

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-177/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-177" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding chemotherapy-induced peripheral neuropathy" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding chemotherapy-induced peripheral neuropathy.">
            <meta name="og:description" content="Read the latest article version by Richard Gordon-Williams, Paul Farquhar-Smith, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23837">
            <meta name="article-id" content="21625">
            <meta name="dc.title" content="Recent advances in understanding chemotherapy-induced peripheral neuropathy">
            <meta name="dc.description" content="Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.">
            <meta name="dc.subject" content="Chemotherapy, Neuropathy, Pain, Survivorship">
            <meta name="dc.creator" content="Gordon-Williams, Richard">
            <meta name="dc.creator" content="Farquhar-Smith, Paul">
            <meta name="dc.date" content="2020/03/11">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21625.1">
            <meta name="dc.source" content="F1000Research 2020 9:177">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Chemotherapy">
            <meta name="prism.keyword" content="Neuropathy">
            <meta name="prism.keyword" content="Pain">
            <meta name="prism.keyword" content="Survivorship">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/03/11">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="177">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21625.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-177">
            <meta name="citation_title" content="Recent advances in understanding chemotherapy-induced peripheral neuropathy">
            <meta name="citation_abstract" content="Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.">
            <meta name="citation_description" content="Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.">
            <meta name="citation_keywords" content="Chemotherapy, Neuropathy, Pain, Survivorship">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Richard Gordon-Williams">
            <meta name="citation_author_institution" content="Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK">
            <meta name="citation_author" content="Paul Farquhar-Smith">
            <meta name="citation_author_institution" content="Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK">
            <meta name="citation_publication_date" content="2020/03/11">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="177">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21625.1">
            <meta name="citation_firstpage" content="177">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-177/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-177.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23837 /> <input type=hidden id=articleId name=articleId value=21625 /> <input type=hidden id=xmlUrl value="/articles/9-177/v1/xml"/> <input type=hidden id=xmlFileName value="-9-177-v1.xml"> <input type=hidden id=article_uuid value=578606ea-9afd-479d-bd7a-71c6826df8bc /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding chemotherapy-induced peripheral neuropathy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21625.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21625.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-177"
  },
  "headline": "Recent advances in understanding chemotherapy-induced peripheral neuropathy",
  "datePublished": "2020-03-11T10:54:32",
  "dateModified": "2020-03-11T10:54:32",
  "author": [
    {
      "@type": "Person",
      "name": "Richard Gordon-Williams"
    },    {
      "@type": "Person",
      "name": "Paul Farquhar-Smith"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-177/v1",
            "name": "Recent advances in understanding chemotherapy-induced peripheral neuropathy"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding chemotherapy-induced peripheral neuropathy </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23837 data-id=21625 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21625.1" data-recommended="" data-doi="10.12688/f1000research.21625.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-177/v1/pdf?article_uuid=578606ea-9afd-479d-bd7a-71c6826df8bc" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21625-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21625-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21625-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):177 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21625.1" target=_blank>https://doi.org/10.12688/f1000research.21625.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21625-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21625 id=track-article-signin-21625 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21625?target=/articles/9-177/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23837 /> <input name=articleId type=hidden value=21625 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding chemotherapy-induced peripheral neuropathy</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:r.gordon-williams@nhs.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard Gordon-Williams</span></a><a href="https://orcid.org/0000-0003-1742-3619" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1742-3619</div>,&nbsp;</span><span class="">Paul Farquhar-Smith</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:r.gordon-williams@nhs.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard Gordon-Williams</span></a><a href="http://orcid.org/0000-0003-1742-3619" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1742-3619</div>,&nbsp;</span><span class="">Paul Farquhar-Smith</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 11 Mar 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21625.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK<br/> <p> <div class=margin-bottom> Richard Gordon-Williams <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Paul Farquhar-Smith <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64372-60342></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64371-60343></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Chemotherapy, Neuropathy, Pain, Survivorship </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Richard Gordon-Williams (<a href="mailto:r.gordon-williams@nhs.net">r.gordon-williams@nhs.net</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Richard Gordon-Williams </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Gordon-Williams R and Farquhar-Smith P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):177 (<a href="https://doi.org/10.12688/f1000research.21625.1" target=_blank>https://doi.org/10.12688/f1000research.21625.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 11 Mar 2020, <b>9</b>(F1000 Faculty Rev):177 (<a href="https://doi.org/10.12688/f1000research.21625.1" target=_blank>https://doi.org/10.12688/f1000research.21625.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 11 Mar 2020, <b>9</b>(F1000 Faculty Rev):177 (<a href="https://doi.org/10.12688/f1000research.21625.1" target=_blank>https://doi.org/10.12688/f1000research.21625.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e142>Introduction</h2><p class="" id=d3628e145>The last decade has heralded improvements in cancer survival<sup><a href="#ref-1">1</a></sup>. However, persistent effects following the treatment of cancer can lead to pain and an impaired quality of life long after treatment has finished or cancer has been cured<sup><a href="#ref-2">2</a></sup>. Chemotherapy-induced peripheral neuropathy (CIPN) is one of those effects that can lead to a continuing symptom burden after treatment<sup><a href="#ref-3">3</a></sup>.</p><p class="" id=d3628e160>CIPN is characterised by the classic “glove and stocking” distribution of symptoms. After chemotherapy, 68% of patients have painful neuropathy at 6 months, improving to 33% at 1 year<sup><a href="#ref-4">4</a></sup>. Although different chemotherapies have variable characteristics, symptoms tend to be predominantly sensory. Sensory toxicity is the predominant feature as dorsal root ganglion (DRG), containing the sensory cell bodies, have a fenestrated endothelium that is more permeable than that found in the spinal cord, where the motor cell bodies lie. Sensory features are characterised by so-called “positive” and “negative” symptoms. “Negative” symptoms include numbness, loss of vibration sense, proprioception and deep tendon reflexes, whereas paraesthesia, dysaesthesia, and cold and mechanical hypersensitivity are referred to as “positive” symptoms.</p><p class="" id=d3628e167>The development of pain is also a common reason for dose reduction<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>, which may have implications for oncological outcome<sup><a href="#ref-6">6</a></sup>. The situation is further complicated by the effect of “coasting”, whereby the development of pain is delayed until after stopping the chemotherapy.</p><p class="" id=d3628e181>Despite advances in cancer treatment and survival, we still have much to learn about CIPN. It is important to recognise that CIPN is a heterogeneous population; it may be acute, such as the neuropathy commonly experienced with oxaliplatin, or chronic, lasting well beyond the end of treatment. Although there may be some overlap in features, it is likely that the underlying pathophysiology, clinical features and therefore its management differ substantially. Furthermore, not all CIPN is considered painful. This review will focus on the mechanisms but also deliberate on clinical features and treatment of chronic painful CIPN.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e187>Animal models</h2><p class="" id=d3628e190>Animal models of CIPN have increased understanding of the pathophysiology of CIPN, yet a recent meta-analysis highlights problems with the current models and may help deliver more robust and valid models<sup><a href="#ref-7">7</a></sup>. For example, how do studies assessing short-term pain behaviours in animals without tumour burden model chronic CIPN? Pre-clinical studies often focus on the gain-of-function symptoms rather than the loss of function (for example, numbness) more common with chronic CIPN. Misrepresentation of the sexes is evident; 83% of animals used were male. Newer models have addressed some of these criticisms. Griffiths <i>et al</i>. describe a paclitaxel model of CIPN for 28 days with ethologically relevant behavioural tests that better mirror the clinical picture<sup><a href="#ref-8">8</a></sup>. Non-human primate models may be more similar to the human condition<sup><a href="#ref-9">9</a></sup> but, owing to ethical and pragmatic issues, are not a feasible alternative to rodents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e211>Mechanisms</h2><p class="" id=d3628e214>The main classes of chemotherapeutics that cause neuropathy include the platinum-based anti-cancer therapies (oxaliplatin and cisplatin), vinca alkaloids (vincristine and vinblastine), taxanes (paclitaxel and docetaxel), proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). These classes have differing anti-neoplastic mechanisms and likely different mechanisms for neuropathy. Evidence suggests that a number of mechanisms are shared between classes of chemotherapeutics, and most studies investigate the taxanes and the platinums. Currently, these mechanisms can be broadly separated into mitochondrial dysfunction and oxidative stress, microtubule disruption, neuroinflammation and immunological processes, and ion channel dysregulation.</p><div class=section><a name=d3628e217 class=n-a></a><h3 class=section-title>Mitochondrial and oxidative stress</h3><p class="" id=d3628e222>Bioenergetic pathways, predominantly via the oxidation of glucose through the Krebs cycle within the mitochondria, are responsible for the generation of ATP. Chemotherapeutics commonly target nucleolar DNA and may also affect mitochondrial DNA. Indeed, targeting mitochondrial DNA as a principal therapy is an area of ongoing research<sup><a href="#ref-10">10</a></sup>. Whereas nucleolar DNA has well-established repair mechanisms, mitochondria do not. Flatters and Bennett showed that paclitaxel treatment in rats led to swollen vacuolated mitochondria that followed the course of pain-like behaviours for almost 3 months<sup><a href="#ref-11">11</a></sup>. Mitochondrial dysfunction within sensory neurones has also been demonstrated by other chemotherapeutics<sup><a href="#ref-12">12</a>–<a href="#ref-15">15</a></sup>. Krukowski <i>et al</i>. found that cisplatin-induced mechanical allodynia is associated with mitochondrial damage in DRG but that the loss of intra-epidermal nerve fibres (IENFs), seen in patients with CIPN, is related to bioenergetic deficits in peripheral nerves<sup><a href="#ref-16">16</a></sup>. Gregg <i>et al</i>. found that post-mortem platinum concentrations in patients who received platinum chemotherapy were highest in DRGs and demonstrated a linear relationship between DRG levels and cumulative dose<sup><a href="#ref-17">17</a></sup>, and levels were higher in patients with neuropathy. Animal data suggest a dose-dependent accumulation within the mitochondria of DRG neurones<sup><a href="#ref-18">18</a></sup>. Recently, gene expression analysis further supported mitochondrial dysfunction in patients who develop CIPN. Kober <i>et al</i>.<sup><a href="#ref-19">19</a></sup> found that breast cancer patients who develop neuropathy after paclitaxel demonstrate differential expression in a number of pathways implicated in mitochondrial dysfunction, including oxidative stress<sup><a href="#ref-20">20</a></sup>. Additionally, genetic polymorphisms in anti-oxidant pathways have been associated with an increased incidence of CIPN<sup><a href="#ref-21">21</a></sup>.</p><p class="" id=d3628e275>Numerous animal studies indicate that chemotherapy worsens oxidative stress<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. Furthermore, anti-oxidants prevent the development of mitochondrial dysfunction, IENF loss and pain-like behaviours in animal models<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>.</p><p class="" id=d3628e292>The anti-oxidant alpha-lipoic acid reduces neuropathy in patients with diabetes and also animal models of CIPN<sup><a href="#ref-26">26</a></sup>. Concurrent administration of alpha-lipoic acid reduces neuropathic symptoms secondary to bortezomib with less alteration to chemotherapy regimen secondary to adverse events<sup><a href="#ref-27">27</a></sup>. However, despite the neuroprotective effects of anti-oxidants <i>in vitro</i> studies<sup><a href="#ref-28">28</a></sup>, there is little clinical evidence for other nutraceutical anti-oxidants in the prevention of CIPN<sup><a href="#ref-29">29</a></sup>. Recently, however, a phase I trial showed that calmangafodipir, a manganese superoxide dismutase mimic that aids reactive oxygen species (ROS) degradation, reduces acute and chronic CIPN after oxaliplatin in patients<sup><a href="#ref-30">30</a></sup> without affecting response to chemotherapy and life expectancy. Metformin can also reduce neuropathic behaviours via a reduction in oxidative stress<sup><a href="#ref-13">13</a>,<a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. Metformin treatment in 40 patients receiving oxaliplatin reduced National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 2 and 3 neuropathy with a moderate reduction in neurotoxicity score and a modest reduction in pain<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d3628e333>Mitochondria play a key role not only in ROS regulation but in numerous other cellular processes, including calcium buffering, apoptosis and energy production via oxidative phosphorylation. Duggett <i>et al</i>. have shown that whereas basal respiration and ATP turnover were unaffected in DRG mitochondria of paclitaxel treated rats, maximal respiration and spare reserve capacity were greatly reduced at peak pain behaviour<sup><a href="#ref-12">12</a></sup>. This indicates a reduced ability of these neurones to respond to stress, and the authors postulated that a switch to glycolysis could be an adaptive mechanism to reduce harmful ROS production.</p><p class="" id=d3628e344>Schwann cells play a crucial role in the regrowth of peripheral axons after injury; however, Nishida <i>et al</i>. found that accumulation of platinum compounds within Schwann cells was much lower than that in peripheral nerves and DRG<sup><a href="#ref-18">18</a></sup>. Conversely, Imai <i>et al</i>. suggested that <i>in vitro</i> platinum compounds cause mitochondrial dysfunction in Schwann cells at drug concentrations lower than those required to induce neurotoxicity<sup><a href="#ref-34">34</a></sup>, suggesting a greater role for mitochondrial dysfunction in Schwann cells in CIPN.</p><p class="" id=d3628e364>In animal models, treatment with pifithrin-μ, a molecule that suppresses mitochondrial damage, improves mitochondrial morphology, bioenergetics and IENF density while reducing pain behaviours<sup><a href="#ref-14">14</a>,<a href="#ref-35">35</a></sup>. Combined with evidence that it may act synergistically with the anti-cancer mechanisms of chemotherapeutics<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>, pifithrin-μ represents an exciting prospect in cancer care.</p></div><div class=section><a name=d3628e382 class=n-a></a><h3 class=section-title>Glia and neuroinflammation</h3><p class="" id=d3628e387>Glia are key in maintaining homeostasis and immunity in the central nervous system in both health and disease. In models of non-chemotherapy-induced neuropathy, microglia have been found to play an integral role in the development of the pain state<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. Oxaliplatin-treated rats displayed persistent mechanical allodynia, sensory deficits and decreased density of IENFs<sup><a href="#ref-39">39</a></sup>. Hu <i>et al</i>. showed a persistent activation of spinal cord microglia through strengthening of triggering receptor expressed on myeloid cells 2 (TREM2) signalling and demonstrated that either inhibiting microglia with minocycline or interrupting TREM2 signalling improved pain-like behaviours and IENF density<sup><a href="#ref-40">40</a></sup>. Furthermore, an agonist at the CB2 cannabinoid receptor, colocalised with spinal microglia, inhibited microgliosis and pain behaviours in an animal model of paclitaxel-induced neuropathy<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d3628e412>Despite these findings, astrogliosis rather than microgliosis is thought to be of greater importance to the development of CIPN<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>, while in some models, astrocyte inhibition with minocycline prevented the development of pain-like behaviours. But how would astrocyte activation lead to the development of CIPN? One proposed mechanism in a rat model of oxaliplatin-induced painful neuropathy is dysregulation of spinal adenosine kinase expression in astrocytes<sup><a href="#ref-44">44</a></sup>. This may lead to activation of NRLP3/interleukin 1 beta (NRLP3/IL1β) pathway, promoting dorsal horn neuronal excitability with concurrent suppression of the anti-inflammatory IL-10 system, leading to central sensitisation and pain behaviours<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. Importantly, restoration of adenosine signalling with an A3AR adenosine receptor agonist prevents the development of both astrocytosis and pain behaviours<sup><a href="#ref-45">45</a></sup>. Another mechanism proposed in rodent models is through the alteration of sphingolipid signalling within astrocytes in the superficial layers of the dorsal horn of the spinal cord, an area concerned with nociceptive transmission<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>. Maladapted sphingolipid metabolism, through direct bortezomib effects and increased IL-1β, may increase glutamatergic transmission and consequently nociceptive transmission and pain behaviours<sup><a href="#ref-47">47</a></sup>.</p><p class="" id=d3628e449>Reasons for the discrepancies in the role glia play in CIPN remain unclear but the discrepancies may be due to variations in chemotherapy, species, time point and sex studied. Pain phenotype differs greatly between male and female patients, and the pathophysiology in animal models is also sex-dependent<sup><a href="#ref-48">48</a></sup>. In animal models of bortezomib-induced peripheral neuropathy, modulation of sphingolipid signalling attenuates pain behaviours in male but not female rodents<sup><a href="#ref-47">47</a></sup>. Additional examples of sexual dimorphism are found in paclitaxel-induced peripheral neuropathy, and Toll-like receptor 9 (TLR9) expression in macrophages infiltrating DRG plays a role in the development of pathophysiological changes and behaviours in male mice but not females<sup><a href="#ref-49">49</a></sup>. Macrophage infiltration into DRG and peripheral nerves has been seen in a number of animal models of CIPN, and as with other models of neuropathic pain, activation of TLR4 seems to be crucial<sup><a href="#ref-50">50</a>–<a href="#ref-52">52</a></sup>.</p><p class="" id=d3628e471>Clinically, minocycline treatment reduced only the acute pain syndrome associated with paclitaxel infusion but not the development of chronic CIPN<sup><a href="#ref-53">53</a></sup>. Additionally, in another phase 2 trial, minocycline failed to prevent oxaliplatin-induced peripheral neuropathy<sup><a href="#ref-54">54</a></sup>. Despite previous pre-clinical trials indicating minocycline’s efficacy at inhibiting astrocyte activation and pain behaviours, its actions have been ascribed predominantly to inhibition of microglia and not astrocytes<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. Given the differential role that microglia may have in CIPN, minocycline’s lack of clinical efficacy may be of no surprise and neuroinflammation still represents a worthy area for continued research in the prevention of CIPN. Fingolimod, a drug used in the treatment of multiple sclerosis, downregulates the S1PR1 receptor found on astrocytes. Antagonism of this receptor has been shown to reverse immunochemical and behavioural changes in rodent models<sup><a href="#ref-47">47</a></sup>. This presents the exciting prospect of a potentially new mechanistic target with a readily available therapeutic agent; however, additional trials are required to assess both its effects on CIPN and importantly tumour activity.</p></div><div class=section><a name=d3628e494 class=n-a></a><h3 class=section-title>Ion channels</h3><p class="" id=d3628e499>Pre-clinical studies have highlighted many chemotherapy-induced changes in ion channel expression, possibly driving behavioural changes in other neuropathic pain states<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d3628e506>Changes in sodium channel expression and their sensitisation increase spontaneous neuronal firing and decrease activation threshold<sup><a href="#ref-58">58</a></sup>, mechanisms possibly analogous to the allodynia, hyperalgesia and paroxysmal sensations of CIPN. In patients, sodium channel dysfunction is found in acute oxaliplatin toxicity<sup><a href="#ref-59">59</a></sup>, and sodium channel polymorphisms may have a causal role in the development of acute and possibly chronic CIPN<sup><a href="#ref-60">60</a></sup>. Furthermore, Na<sub>v</sub>1.7 channel has been found to be similarly upregulated in nociceptive neurones in both a rat model and patients with chronic paclitaxel-induced peripheral neuropathy<sup><a href="#ref-61">61</a></sup>. Although dysregulation of other sodium channels is seen in pre-clinical studies of CIPN<sup><a href="#ref-62">62</a></sup>, the clinical efficacy of sodium channel blockers has been disappointing<sup><a href="#ref-63">63</a></sup>.</p><p class="" id=d3628e537>Potassium channel dysregulation is present in animal models of CIPN<sup><a href="#ref-64">64</a></sup>. Acutely, oxaliplatin leads to the down-regulation of potassium channels in animal models<sup><a href="#ref-62">62</a></sup>, and Poupon <i>et al</i>. found that treatment with a riluzole (a potassium channel activator) prevents the development of persistent CIPN in mice<sup><a href="#ref-65">65</a></sup>. A phase 2 randomised controlled trial (RCT) investigating the efficacy of riluzole in the prevention of CIPN is under way<sup><a href="#ref-66">66</a></sup>. Transient receptor potential (TRP) channels are critical in temperature transduction. Oxaliplatin treatment leads to an increased expression of TRPA1, TRPV1 and TRPM8 in sensory neurones<sup><a href="#ref-67">67</a></sup>. Interestingly, suppression of TREK-1 and TRAAK potassium channels (and an increase in pro-excitatory Na<sub>v</sub>1.8 and HCN ion channels) is found on neurones expressing TRPM8, a receptor responsive to cold<sup><a href="#ref-62">62</a></sup>. This may present a mechanism through which menthol provides symptomatic relief and oxaliplatin produces cold hypersensitivity acutely.</p><p class="" id=d3628e571>Although calcium channel modulation has shown promise in animal models of CIPN<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>, no direct calcium channel blockers are in clinical use for neuropathic pain. Cisplatin causes an increase in the calcium channel alpha-2-delta subunit, the target of gabapentinoids<sup><a href="#ref-70">70</a></sup>, and both topical and systemic treatment with gabapentinoids have been found to be beneficial in rat models of CIPN<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. Despite this, treatment with pregabalin for 3 days before and after each cycle of oxaliplatin failed to prevent CIPN in patients<sup><a href="#ref-73">73</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e600>Clinical features</h2><div class=section><a name=d3628e603 class=n-a></a><h3 class=section-title>Risk factors</h3><p class="" id=d3628e608>There are many potential predictors in the development of CIPN, including patient-related factors, such as increased age, pre-existing neuropathy, smoking status, and impaired renal function, and chemotherapy-related factors, such as type of chemotherapy, cumulative chemotherapy dose, concurrent chemotherapy treatment, and duration of infusion<sup><a href="#ref-74">74</a>–<a href="#ref-76">76</a></sup>. Certain cancers may cause a subclinical neuropathy which may predispose patients to CIPN and worsen outcomes<sup><a href="#ref-77">77</a></sup>.</p><p class="" id=d3628e622>Genetic markers have been implicated in chemotherapy-related toxicity, and a number of genome-wide association studies have looked at polymorphisms associated with CIPN. A number of polymorphisms have been identified, none of which (at present) has sufficient prognostic value to be of use in the clinical context<sup><a href="#ref-78">78</a></sup>. Argyriou <i>et al</i>.<sup><a href="#ref-78">78</a></sup> called for improved methodology and more standardised diagnostic and severity grading to better inform future studies.</p></div><div class=section><a name=d3628e637 class=n-a></a><h3 class=section-title>Assessment of CIPN</h3><p class="" id=d3628e642>Despite challenges in prevention and treatment, assessment for CIPN should occur before, during and after chemotherapy. Assessment should include (1) diagnosis (including possible differential diagnoses), (2) severity (including functional impairment) and (3) time course of symptoms and relationship to chemotherapy.</p><p class="" id=d3628e645>Diagnosis of CIPN requires a full history and examination (<a href="#T1">Table 1</a>). Within the history, it is important to determine pre-existing risk factors for neuropathy such as diabetes, vitamin deficiency, alcohol use and previous chemotherapy. Blood tests, including a full blood count, comprehensive metabolic profile, measurement of erythrocyte sedimentation rate, fasting blood glucose, vitamin B<sub>12</sub>, and thyroid-stimulating hormone levels, should be considered to help rule out other causative or contributory causes for neuropathy.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Key elements in history and examination.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d3628e665 class=n-a></a><thead><a name=d3628e667 class=n-a></a><tr><a name=d3628e669 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d3628e671 class=n-a></a>History</th><th align=left colspan=1 rowspan=1 valign=top><a name=d3628e674 class=n-a></a>Examination</th></tr></thead><tbody><a name=d3628e679 class=n-a></a><tr><a name=d3628e681 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d3628e683 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Details of chemotherapy regimen<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Number of cycles, dose and cumulative dose<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Onset of symptoms in relation to chemotherapy<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;“Coasting” assessment (neuropathy occurring or<br class=br>worsening after chemotherapy cessation)<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Evidence of change over time (better or worse)<br class=br><br class=br>Symptoms<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Distribution (hands, feet or more proximal)<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Numbness, paraesthesia, pain, spontaneous or evoked<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Motor or sympathetic dysfunction<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Functionality and interference on activities</td><td align=left colspan=1 rowspan=1 valign=top><a name=d3628e717 class=n-a></a>Sensation<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Light touch<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Pinprick or painful stimulus<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Vibration sense<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Cold/hot sensation<br class=br><br class=br>Other<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Deep tendon reflexes<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Motor power<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Balance</td></tr></tbody></table></div><p class="" id=d3628e750>Painful CIPN is a subset that may benefit from further characterisation with multidimensional pain assessment tools. The McGill Pain Questionnaire (MPQ) and the Brief Pain Inventory (BPI) have been validated for use in cancer pain<sup><a href="#ref-79">79</a></sup> and although they both assess sensory aspects, including severity, the BPI also assesses impact on function. Likewise, screening tools may aid in the assessment of neuropathic pain. Two such tools, the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and Douleur Neuropathique 4 (DN4)<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>, have good sensitivity and specificity in cancer pain but are not validated in CIPN. Furthermore, although chemotherapy is a common treatment for childhood cancers and the subsequent neuropathy may differ in phenotype from that of adults<sup><a href="#ref-82">82</a>,<a href="#ref-83">83</a></sup>, there are few validated tools for the assessment of CIPN in children. One such score is the paediatric-modified total neuropathy score (ped-mTNS), which has been validated in a small group of children undergoing vincristine or cisplatin chemotherapy for leukaemia<sup><a href="#ref-84">84</a></sup>; however, the 2008 Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (PedIMMPACT) called for the development of reliable and valid tools for use in children<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d3628e780>Numerous tools have been developed for the assessment of CIPN; however, there is notable inter-observer variation between these scales. Clinical rated scales such as the Ajani scale, World Health Organization, Eastern Cooperative Oncology Group neuropathy scale, and NCI-Common Toxicity Criteria (NCI-CTC) have limited assessment of pain<sup><a href="#ref-86">86</a></sup> and may not truly reflect the incidence of adverse neuropathy, leading to inappropriate treatment reduction or cessation. Furthermore, clinician-rated neuropathy scales underestimate the severity of CIPN when compared with patient-reported measures<sup><a href="#ref-87">87</a></sup>. In a recent systematic review, Haryani <i>et al</i>. suggested that, owing to their psychometric properties and practicality, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) and total neuropathy score (TNS) (see below) were the most appropriate assessment tools available<sup><a href="#ref-88">88</a></sup>. Yet other studies are contradictory; this is in line with a recent DELPHI survey which showed there is little consensus amongst clinicians<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d3628e802>Fact/GOG-Ntx was developed for assessing the impact of neuropathy on quality of life after chemotherapy for gynaecological cancer and consists of questions on physical, social, emotional and functional wellbeing with an additional 11-question neurotoxicity subscale. This subscale has been used independently and demonstrates good sensitivity in diagnosis and responsiveness to treatment<sup><a href="#ref-90">90</a></sup> and has been validated in other non-gynaecological, non-cisplatin/paclitaxel patients. Further shortening the neurotoxic subscale to four sensory questions maintains the validity and sensitivity while reducing the burden of patient questions<sup><a href="#ref-91">91</a></sup>.</p><p class="" id=d3628e813>The Patient Neurotoxicity Questionnaire (PNQ) evaluates sensory, motor and functional components of neuropathy with good sensitivity to change over time and showed improved reporting of CIPN when compared with clinician reporting tools such as the NCI-CTC (see above). Importantly, the PNQ assesses the impact of neuropathy on 22 activities (such as fastening buttons or typing) that are not assessed with other tools, thus representing a more holistic patient-centred assessment of neuropathy.</p><p class="" id=d3628e816>The TNS is an eight-item score of patient report of neuropathic symptoms, examination findings to pinprick, vibration and deep tendon reflexes and nerve conduction studies (NCSs). A shortened version without the electrophysiological factors has been validated: the TNSc (clinical version of the TNS)<sup><a href="#ref-92">92</a></sup>; both have been shown to be more sensitive to CIPN changes than NCI-CTC and comparable in changes to quality-of-life measures<sup><a href="#ref-93">93</a></sup>. Importantly, TNS delivers both clinician- and patient-rated components. Quality-of-life measures are commonly not assessed in many CIPN tools. The European Organization of Research and Treatment of Cancer (EORTC), 20-item quality-of-life questionnaire, is sensitive to changes in quality of life secondary to CIPN<sup><a href="#ref-94">94</a></sup>.</p></div><div class=section><a name=d3628e832 class=n-a></a><h3 class=section-title>Investigations</h3><p class="" id=d3628e837>There has been a great deal of interest in phenotyping CIPN by using minimally invasive tools such as NCSs, quantitative sensory testing (QST) and IENF density. It seems sensible that underlying mechanisms may translate to differing patterns of neuronal loss and therefore differences in functional deficits, yet in practice this theory is not robust. Traditionally, CIPN has been characterised as a predominant sensory neuropathy effecting large myelinated fibre function, and nerve biopsies from patients with cisplatin- and paclitaxel-induced neuropathy show a loss of large fibres with axonal atrophy and secondary demyelination<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>.</p><p class="" id=d3628e847>Platinum chemotherapeutics cause neuronal cycle arrest within the DRG and therefore likely cause a neuronopathy (also referred to as ganglionopathy) and anterograde neuronal degeneration. On NCS, this would manifest as non-length-dependent neuropathy affecting both the proximal and distal neurone. In contrast, chemotherapeutics interfering with mitochondrial or microtubule function impair axonal transportation giving a length-dependent axonal polyneuropathy, leading to a die back of intraepidermal nerve fibres. However, owing to poor correlation with clinical symptoms, NCSs cannot be routinely recommended. Furthermore, NCSs assess predominantly large-fibre function, missing small-fibre changes that may occur with painful CIPN.</p><p class="" id=d3628e850>Owing to its ability to assess large- and small-fibre types, QST may be of use in the phenotyping of neuropathic pain<sup><a href="#ref-97">97</a></sup> and therefore has been proposed as a useful tool in CIPN<sup><a href="#ref-98">98</a></sup>. In patients with paclitaxel-induced peripheral neuropathy, the reduction in light touch and vibration detection thresholds seen in hands and feet supports the mechanism of paclitaxel causing a distal neuropathy predominantly effecting the large, non-nociceptive neurones<sup><a href="#ref-99">99</a></sup>. Additionally, some report that thermal detection thresholds and pinprick detection are minimally affected, indicating that small-fibre function is preserved in this group. This is in contrast to findings in patients with vincristine and bortezomib-induced neuropathy, with some studies reporting changes in pinprick perception and warm detection thresholds suggesting small, nociceptive fibre dysfunction in this group of patients<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>.</p><p class="" id=d3628e872>Pre-existing QST sensory deficits increase the risk of developing CIPN<sup><a href="#ref-102">102</a></sup>; in some cases, cancer itself may be responsible for QST changes<sup><a href="#ref-103">103</a></sup>. Although the QST sensory profile may differ between agents<sup><a href="#ref-104">104</a>,<a href="#ref-105">105</a></sup>, QST profiles for painful and painless CIPN may be similar<sup><a href="#ref-106">106</a></sup> and changes in QST may occur later than symptoms develop<sup><a href="#ref-107">107</a></sup>. Furthermore, QST requires expertise and time and consequently is not commonly used in routine clinical practice for the evaluation of CIPN.</p><p class="" id=d3628e899>Skin punch biopsy can inform the diagnosis of small-fibre neuropathies. In CIPN, similar to other small-fibre neuropathies, IENF loss is observed<sup><a href="#ref-108">108</a></sup>. Taking comparative distal thigh and distal leg punch biopsies can help differentiate between a length-dependent neuropathy or a neuronopathy; however, evaluating CIPN using IENF densities has been found to be unreliable; there is a large overlap between different chemotherapeutics, and results conflict with other assessment tools<sup><a href="#ref-109">109</a>–<a href="#ref-111">111</a></sup>. Furthermore, although punch biopsy can be repeated, it is time-consuming and invasive and IENF density has been found to be a poor correlate of pain<sup><a href="#ref-112">112</a></sup>.</p><p class="" id=d3628e917>Other techniques for assessing neuropathy have yet to be fully validated. Nevertheless, simple bedside measures such as vibration sense, light touch and pinprick have good validity in the measurement of neuropathy<sup><a href="#ref-113">113</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e928>Prevention</h2><p class="" id=d3628e931>Reducing regional perfusion (cryotherapy) may reduce CIPN; cooling gloves and stockings have been shown to reduce the risk of desquamation and nail changes associated with chemotherapy. Of the three published trials, only one showed benefit<sup><a href="#ref-114">114</a></sup>. Owing to poorly tolerated treatment or a greater-than-expected control group response, the other studies were negative<sup><a href="#ref-115">115</a>–<a href="#ref-117">117</a></sup>.</p><p class="" id=d3628e945>In 2014, the American Society of Clinical Oncology evaluated 42 studies while developing guidelines on the prevention of CIPN<sup><a href="#ref-63">63</a></sup>. Owing to a lack of high-quality data, they were unable to make any recommendations and encouraged additional research.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e956>Treatment</h2><div class=section><a name=d3628e959 class=n-a></a><h3 class=section-title>Pharmacological</h3><p class="" id=d3628e964>RCT evidence of treatments in CIPN suggested that duloxetine is the only anti-neuropathic agent with evidence of benefit<sup><a href="#ref-118">118</a></sup>. Many CIPN RCTs fail to meet the IMMPACT guidelines for outcome measures in clinical trials<sup><a href="#ref-119">119</a>,<a href="#ref-120">120</a></sup>. Nevertheless, a recent comparative study showed that venlafaxine and duloxetine reduced pain in established CIPN<sup><a href="#ref-121">121</a></sup>. Careful phenotyping may help, as demonstrated with the improved efficacy of oxcarbazepine in the “irritable nociceptor” subgroup<sup><a href="#ref-122">122</a></sup>. Phenotyping patients for biological and psychosocial characteristics may give additional insight<sup><a href="#ref-122">122</a>–<a href="#ref-125">125</a></sup>.</p><p class="" id=d3628e993>Topical treatments are an attractive option for the management of CIPN. A small non-randomised study of topical menthol in 52 patients showed improved BPI scores<sup><a href="#ref-126">126</a></sup>, and combination therapy with baclofen, amitriptyline and ketamine showed an improvement on some of the EORTC QLQ-CIPN-20 measures<sup><a href="#ref-127">127</a></sup>. Topical 8% capsaicin patch application following CIPN has been shown to improve continuous pain, neuropathic pain symptoms, and patient global impression of change<sup><a href="#ref-128">128</a></sup>. This treatment has also been found to improve IENF density, suggesting underlying disease modification<sup><a href="#ref-128">128</a></sup>.</p><p class="" id=d3628e1012>There is increasing enthusiasm for the use of cannabinoids in the treatment of many chronic pain states. Agonism at CB1 and CB2 receptors has shown analgesia in rodent models of CIPN<sup><a href="#ref-129">129</a>–<a href="#ref-133">133</a></sup> but these findings have not translated into evidence of clinical efficacy. One published pilot study of nabiximols (THC:CBD mix) in 15 patients with CIPN<sup><a href="#ref-134">134</a></sup> showed no significant improvement in pain, but a 2-point decrease over placebo was seen in five patients classified as “responders”<sup><a href="#ref-134">134</a></sup>.</p><p class="" id=d3628e1030>Without specific evidence for CIPN, clinicians extrapolate treatments from other neuropathic pain states<sup><a href="#ref-135">135</a></sup>. Interestingly, strong opioids have some of the best “numbers needed to treat” (NNTs) for neuropathic pain (NNT 4.3, 95% confidence interval 3.4–5.8)<sup><a href="#ref-135">135</a></sup>. Some clinicians may advocate the use of opioids in CIPN, however with increasing survivorship amongst patients with cancer, the possible benefits of opioids should be continually weighed up against the risk of long-term opioid therapy<sup><a href="#ref-2">2</a></sup>.</p></div><div class=section><a name=d3628e1046 class=n-a></a><h3 class=section-title>Non-pharmacological</h3><p class="" id=d3628e1051>Neuromodulation has shown promise in various neuropathic pain states<sup><a href="#ref-136">136</a></sup>. A number of case reports indicate that neuromodulation may help refractory CIPN<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup>, but RCT data are lacking.</p><p class="" id=d3628e1065>A recent study found that the use of wireless transcutaneous electrical nerve stimulation significantly improved some measures of CIPN, including pain, numbness and tingling<sup><a href="#ref-139">139</a></sup>. Furthermore, scrambler therapy (a novel transcutaneous neurostimulation technique) has been postulated as a potential treatment<sup><a href="#ref-140">140</a></sup> but was no more effective than sham therapy in a recent RCT<sup><a href="#ref-141">141</a></sup>.</p></div><div class=section><a name=d3628e1081 class=n-a></a><h3 class=section-title>Acupuncture</h3><p class="" id=d3628e1086>A Cochrane Review of the efficacy of acupuncture in the treatment of cancer pain showed insufficient evidence of its efficacy<sup><a href="#ref-142">142</a></sup>. Since then, a number of trials of acupuncture in CIPN have demonstrated improvements in several domains<sup><a href="#ref-143">143</a>–<a href="#ref-145">145</a></sup>. A systematic review concluded that there was insufficient evidence to recommend acupuncture for the treatment of CIPN<sup><a href="#ref-146">146</a></sup>, although low risk of harm and possible benefit may allow its pragmatic use in painful CIPN.</p></div><div class=section><a name=d3628e1105 class=n-a></a><h3 class=section-title>Physical therapy</h3><p class="" id=d3628e1110>Exercise has been shown to improve a number of facets that contribute to morbidity associated with CIPN, including balance and strength<sup><a href="#ref-147">147</a>,<a href="#ref-148">148</a></sup>, numbness, tingling, and hot and cold sensations<sup><a href="#ref-149">149</a></sup>. One study found that, on analysis of the quality-of-life data, exercise had a moderate effect on pain in patients undergoing chemotherapy; however, this was not limited to CIPN<sup><a href="#ref-150">150</a></sup>.</p></div><div class=section><a name=d3628e1130 class=n-a></a><h3 class=section-title>Psychological therapy</h3><p class="" id=d3628e1135>Psychological factors have been shown to play a role in both the initiation and maintenance of a number of chronic pain states<sup><a href="#ref-151">151</a></sup>. The activity of duloxetine, via enhancing descending inhibitory pathways, suggests that alteration of mood may play a role. In favour of this viewpoint, a study of 111 patients who received treatment for breast cancer found that pre-existing anxiety and pre-therapy numbness were the only factors to predict CIPN eight months later<sup><a href="#ref-152">152</a></sup>. Knoerl <i>et al</i>. found that an eight-week web-based cognitive behavioural programme led to modest improvements in worst pain with no differences in mean pain<sup><a href="#ref-153">153</a></sup>. It was hypothesised that this would be due to improvements in fatigue, anxiety, sleep-related factors, or depression; however, a follow-up analysis was unable to substantiate these findings<sup><a href="#ref-154">154</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e1161>Future directions</h2><p class="" id=d3628e1164>Pre-clinical studies have shown that antagonism of the sigma 1 receptor (present on mitochondrial endoplasmic reticulum) is able to reduce mitochondrial structural changes and pain behaviours that occur in CIPN. A phase II clinical trial found that sigma 1 antagonist treatment during FOLFOX chemotherapy diminished cold hypersensitivity, reduced the dropout rate and allowed a higher cumulative dose of oxaliplatin<sup><a href="#ref-155">155</a></sup>. Although the long-term pain outcomes are not known, this highlights a pathway for potential therapeutics that could improve CIPN.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3628e1174>Summary</h2><p class="" id=d3628e1177>Despite an ever-expanding body of literature behind the pathophysiology and treatment of CIPN, new treatment options are still limited, and a proportion of patients continue to have difficulty controlling symptoms causing a significant impact on quality of life. Guided by the pre-clinical literature, novel targets that may help prevent CIPN are beginning to emerge. However, with continual advancements in chemotherapeutic agents with novel mechanisms, it is important that ongoing development of treatments for CIPN continue.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d3628e1184 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d4673>References</h2><div class="section ref-list"><a name=d3628e1184 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d3628e1191 class=n-a></a>Arnold M, Rutherford MJ, Bardot A, <i> et al.</i>: Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. <i>Lancet Oncol.</i> 2019; <b>20</b>(11): 1493–505. <a target=xrefwindow id=d3628e1202 href="http://www.ncbi.nlm.nih.gov/pubmed/31521509">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1205 href="https://doi.org/10.1016/S1470-2045(19)30456-5">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1209 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6838671">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d3628e1218 class=n-a></a>Brown M, Farquhar-Smith P: Pain in cancer survivors; filling in the gaps. <i>Br J Anaesth.</i> 2017; <b>119</b>(4): 723–36. <a target=xrefwindow id=d3628e1226 href="http://www.ncbi.nlm.nih.gov/pubmed/29121290">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1229 href="https://doi.org/10.1093/bja/aex202">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d3628e1238 class=n-a></a>Mols F, Beijers T, Vreugdenhil G, <i> et al.</i>: Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. <i>Support Care Cancer.</i> 2014; <b>22</b>(8): 2261–9. <a target=xrefwindow id=d3628e1249 href="http://www.ncbi.nlm.nih.gov/pubmed/24789421">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1252 href="https://doi.org/10.1007/s00520-014-2255-7">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d3628e1261 class=n-a></a>Seretny M, Currie GL, Sena ES, <i> et al.</i>: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. <i>Pain.</i> 2014; <b>155</b>(12): 2461–70. <a target=xrefwindow id=d3628e1272 href="http://www.ncbi.nlm.nih.gov/pubmed/25261162">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1275 href="https://doi.org/10.1016/j.pain.2014.09.020">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d3628e1284 class=n-a></a>Gutiérrez-Gutiérrez G, Sereno M, Miralles A, <i> et al.</i>: Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. <i>Clin Transl Oncol.</i> 2010; <b>12</b>(2): 81–91. <a target=xrefwindow id=d3628e1295 href="http://www.ncbi.nlm.nih.gov/pubmed/20156778">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1298 href="https://doi.org/10.1007/S12094-010-0474-z">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d3628e1308 class=n-a></a>Bhatnagar B, Gilmore S, Goloubeva O, <i> et al.</i>: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. <i>SpringerPlus.</i> 2014; <b>3</b>: 366. <a target=xrefwindow id=d3628e1319 href="http://www.ncbi.nlm.nih.gov/pubmed/25089251">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1322 href="https://doi.org/10.1186/2193-1801-3-366">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4117856">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d3628e1335 class=n-a></a>Currie GL, Angel-Scott HN, Colvin L, <i> et al.</i>: Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis. <i>PLoS Biol.</i> 2019; <b>17</b>(5): e3000243. <a target=xrefwindow id=d3628e1346 href="http://www.ncbi.nlm.nih.gov/pubmed/31107871">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1349 href="https://doi.org/10.1371/journal.pbio.3000243">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6544332">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d3628e1362 class=n-a></a>Griffiths LA, Duggett NA, Pitcher AL, <i> et al.</i>: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. <i>Pain Res Manag.</i> 2018; <b>2018</b>: 8217613. <a target=xrefwindow id=d3628e1373 href="http://www.ncbi.nlm.nih.gov/pubmed/29973969">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1376 href="https://doi.org/10.1155/2018/8217613">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1380 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6008701">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d3628e1389 class=n-a></a>Hama A, Natsume T, Ogawa S, <i> et al.</i>: Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain. <i>Pain Res Manag.</i> 2018; <b>2018</b>: 1630709. <a target=xrefwindow id=d3628e1400 href="http://www.ncbi.nlm.nih.gov/pubmed/29854035">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1403 href="https://doi.org/10.1155/2018/1630709">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1407 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5954874">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d3628e1416 class=n-a></a>Wisnovsky SP, Wilson JJ, Radford RJ, <i> et al.</i>: Targeting mitochondrial DNA with a platinum-based anticancer agent. <i>Chem Biol.</i> 2013; <b>20</b>(11): 1323–8. <a target=xrefwindow id=d3628e1427 href="http://www.ncbi.nlm.nih.gov/pubmed/24183971">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1430 href="https://doi.org/10.1016/j.chembiol.2013.08.010">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1434 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4082333">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d3628e1443 class=n-a></a>Flatters SJL, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. <i>Pain.</i> 2006; <b>122</b>(3): 245–57. <a target=xrefwindow id=d3628e1451 href="http://www.ncbi.nlm.nih.gov/pubmed/16530964">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1454 href="https://doi.org/10.1016/j.pain.2006.01.037">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1457 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1805481">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d3628e1467 class=n-a></a>Duggett NA, Griffiths LA, Flatters SJL: Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. <i>Pain.</i> 2017; <b>158</b>(8): 1499–508. <a target=xrefwindow id=d3628e1475 href="http://www.ncbi.nlm.nih.gov/pubmed/28541258">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1478 href="https://doi.org/10.1097/j.pain.0000000000000939">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5515641">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d3628e1490 class=n-a></a>Ludman T, Melemedjian OK: Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy. <i>Mol Pain.</i> 2019; <b>15</b>: 174480691985004. <a target=xrefwindow id=d3628e1498 href="http://www.ncbi.nlm.nih.gov/pubmed/31041875">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1501 href="https://doi.org/10.1177/1744806919850043">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6509977">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d3628e1513 class=n-a></a>Maj MA, Ma J, Krukowski KN, <i> et al.</i>: Inhibition of Mitochondrial p53 Accumulation by PFT-μ Prevents Cisplatin-Induced Peripheral Neuropathy. <i>Front Mol Neurosci.</i> 2017; <b>10</b>: 108. <a target=xrefwindow id=d3628e1524 href="http://www.ncbi.nlm.nih.gov/pubmed/28458631">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1527 href="https://doi.org/10.3389/fnmol.2017.00108">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394177">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d3628e1540 class=n-a></a>Xiao WH, Zheng H, Zheng FY, <i> et al.</i>: Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. <i>Neuroscience.</i> 2011; <b>199</b>: 461–9. <a target=xrefwindow id=d3628e1551 href="http://www.ncbi.nlm.nih.gov/pubmed/22037390">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1554 href="https://doi.org/10.1016/j.neuroscience.2011.10.010">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1558 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3237950">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d3628e1567 class=n-a></a>Krukowski K, Ma J, Golonzhka O, <i> et al.</i>: HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. <i>Pain.</i> 2017; <b>158</b>(6): 1126–37. <a target=xrefwindow id=d3628e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/28267067">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1581 href="https://doi.org/10.1097/j.pain.0000000000000893">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5435512">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d3628e1594 class=n-a></a>Gregg RW, Molepo JM, Monpetit VJ, <i> et al.</i>: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. <i>J Clin Oncol.</i> 1992; <b>10</b>(5): 795–803. <a target=xrefwindow id=d3628e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/1569451">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1608 href="https://doi.org/10.1200/JCO.1992.10.5.795">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d3628e1618 class=n-a></a>Nishida K, Takeuchi K, Hosoda A, <i> et al.</i>: Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. <i>Life Sci.</i> 2018; <b>207</b>: 516–24. <a target=xrefwindow id=d3628e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/29981320">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1632 href="https://doi.org/10.1016/j.lfs.2018.07.006">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d3628e1641 class=n-a></a>Kober KM, Olshen A, Conley YP, <i> et al.</i>: Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. <i>Mol Pain.</i> 2018; <b>14</b>: 174480691881646. <a target=xrefwindow id=d3628e1652 href="http://www.ncbi.nlm.nih.gov/pubmed/30426838">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1655 href="https://doi.org/10.1177/1744806918816462">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1659 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6293373">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d3628e1668 class=n-a></a>Ziegler D, Hanefeld M, Ruhnau KJ, <i> et al.</i>: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). <i>Diabetologia.</i> 1995; <b>38</b>(12): 1425–33. <a target=xrefwindow id=d3628e1679 href="http://www.ncbi.nlm.nih.gov/pubmed/8786016">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1682 href="https://doi.org/10.1007/bf00400603">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d3628e1691 class=n-a></a>Katayanagi S, Katsumata K, Mori Y, <i> et al.</i>: <i>GSTP1</i> as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. <i>Oncol Lett.</i> 2019; <b>17</b>(3): 2897–2904. <a target=xrefwindow id=d3628e1705 href="http://www.ncbi.nlm.nih.gov/pubmed/30854066">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1709 href="https://doi.org/10.3892/ol.2019.9907">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6365892">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d3628e1721 class=n-a></a>Ma J, Kavelaars A, Dougherty PM, <i> et al.</i>: Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. <i>Cancer.</i> 2018; <b>124</b>(11): 2289–98. <a target=xrefwindow id=d3628e1732 href="http://www.ncbi.nlm.nih.gov/pubmed/29461625">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1735 href="https://doi.org/10.1002/cncr.31248">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1739 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5991994">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d3628e1748 class=n-a></a>Shim HS, Bae C, Wang J, <i> et al.</i>: Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. <i>Mol Pain.</i> 2019; <b>15</b>: 1744806919840098. <a target=xrefwindow id=d3628e1759 href="http://www.ncbi.nlm.nih.gov/pubmed/30857460">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1762 href="https://doi.org/10.1177/1744806919840098">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6458664">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d3628e1776 class=n-a></a>Janes K, Doyle T, Bryant L, <i> et al.</i>: Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. <i>Pain.</i> 2013; <b>154</b>(11): 2432–40. <a target=xrefwindow id=d3628e1787 href="http://www.ncbi.nlm.nih.gov/pubmed/23891899">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1790 href="https://doi.org/10.1016/j.pain.2013.07.032">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4870004">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d3628e1803 class=n-a></a>Jin HW, Flatters SJ, Xiao WH, <i> et al.</i>: Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. <i>Exp Neurol.</i> 2008; <b>210</b>(1): 229–37. <a target=xrefwindow id=d3628e1814 href="http://www.ncbi.nlm.nih.gov/pubmed/18078936">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1817 href="https://doi.org/10.1016/j.expneurol.2007.11.001">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2323600">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d3628e1830 class=n-a></a>Papanas N, Ziegler D: Efficacy of α-lipoic acid in diabetic neuropathy. <i>Expert Opin Pharmacother.</i> 2014; <b>15</b>(18): 2721–31. <a target=xrefwindow id=d3628e1838 href="http://www.ncbi.nlm.nih.gov/pubmed/25381809">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1841 href="https://doi.org/10.1517/14656566.2014.972935">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d3628e1850 class=n-a></a>Maschio M, Zarabla A, Maialetti A, <i> et al.</i>: Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integr Cancer Ther.</i> 2018; <b>17</b>(4): 1115–24. <a target=xrefwindow id=d3628e1861 href="http://www.ncbi.nlm.nih.gov/pubmed/30295079">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1864 href="https://doi.org/10.1177/1534735418803758">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1868 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6247541">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d3628e1877 class=n-a></a>Popović J, Klajn A, Paunesku T, <i> et al.</i>: Neuroprotective Role of Selected Antioxidant Agents in Preventing Cisplatin-Induced Damage of Human Neurons <i>In Vitro</i>. <i>Cell Mol Neurobiol.</i> 2019; <b>39</b>(5): 619–36. <a target=xrefwindow id=d3628e1891 href="http://www.ncbi.nlm.nih.gov/pubmed/30874981">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1895 href="https://doi.org/10.1007/s10571-019-00667-7">Publisher Full Text </a> | <a target=xrefwindow id=d3628e1898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6535150">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d3628e1907 class=n-a></a>Schloss JM, Colosimo M, Airey C, <i> et al.</i>: Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. <i>Clin Nutr.</i> 2013; <b>32</b>(6): 888–93. <a target=xrefwindow id=d3628e1918 href="http://www.ncbi.nlm.nih.gov/pubmed/23647723">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1921 href="https://doi.org/10.1016/j.clnu.2013.04.007">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d3628e1931 class=n-a></a>Glimelius B, Manojlovic N, Pfeiffer P, <i> et al.</i>: Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx<sup>®)</sup>: a placebo-controlled randomised phase II study (PLIANT). <i>Acta Oncol.</i> 2018; <b>57</b>(3): 393–402. <a target=xrefwindow id=d3628e1945 href="http://www.ncbi.nlm.nih.gov/pubmed/29140155">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1949 href="https://doi.org/10.1080/0284186X.2017.1398836">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d3628e1958 class=n-a></a>Chakraborty A, Chowdhury S, Bhattacharyya M: Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. <i>Diabetes Res Clin Pract.</i> 2011; <b>93</b>(1): 56–62. <a target=xrefwindow id=d3628e1966 href="http://www.ncbi.nlm.nih.gov/pubmed/21146883">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1969 href="https://doi.org/10.1016/j.diabres.2010.11.030">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d3628e1978 class=n-a></a>Hou X, Song J, Li XN, <i> et al.</i>: Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. <i>Biochem Biophys Res Commun.</i> 2010; <b>396</b>(2): 199–205. <a target=xrefwindow id=d3628e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/20398632">PubMed Abstract </a> | <a target=xrefwindow id=d3628e1992 href="https://doi.org/10.1016/j.bbrc.2010.04.017">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d3628e2001 class=n-a></a>El-Fatatry BM, Ibrahim OM, Hussien FZ, <i> et al.</i>: Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. <i>Int J Colorectal Dis.</i> 2018; <b>33</b>(12): 1675–83. <a target=xrefwindow id=d3628e2012 href="http://www.ncbi.nlm.nih.gov/pubmed/29931409">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2015 href="https://doi.org/10.1007/s00384-018-3104-9">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d3628e2024 class=n-a></a>Imai S, Koyanagi M, Azimi Z, <i> et al.</i>: Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. <i>Sci Rep.</i> 2017; <b>7</b>(1): 5947. <a target=xrefwindow id=d3628e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/28729624">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2038 href="https://doi.org/10.1038/s41598-017-05784-1">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5519765">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d3628e2051 class=n-a></a>Krukowski K, Nijboer CH, Huo X, <i> et al.</i>: Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ. <i>Pain.</i> 2015; <b>156</b>(11): 2184–92. <a target=xrefwindow id=d3628e2062 href="http://www.ncbi.nlm.nih.gov/pubmed/26473292">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2065 href="https://doi.org/10.1097/j.pain.0000000000000290">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4900465">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d3628e2079 class=n-a></a>McKeon A, Egan A, Chandanshive J, <i> et al.</i>: Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin-μ. <i>In Vitro</i> Synergy Quantification of Pifithrin-μ Combined with Pt Drugs in Prostate and Colorectal Cancer Cells. <i>Molecules.</i> 2016; <b>21</b>(7): pii: E949. <a target=xrefwindow id=d3628e2093 href="http://www.ncbi.nlm.nih.gov/pubmed/27455212">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2097 href="https://doi.org/10.3390/molecules21070949">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2100 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6273252">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d3628e2109 class=n-a></a>Zhao H, Alam A, Chen Q, <i> et al.</i>: The role of microglia in the pathobiology of neuropathic pain development: what do we know? <i>Br J Anaesth.</i> 2017; <b>118</b>(4): 504–16. <a target=xrefwindow id=d3628e2120 href="http://www.ncbi.nlm.nih.gov/pubmed/28403399">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2123 href="https://doi.org/10.1093/bja/aex006">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d3628e2132 class=n-a></a>Sayo A, Konishi H, Kobayashi M, <i> et al.</i>: GPR34 in spinal microglia exacerbates neuropathic pain in mice. <i>J Neuroinflammation.</i> 2019; <b>16</b>(1): 82. <a target=xrefwindow id=d3628e2143 href="http://www.ncbi.nlm.nih.gov/pubmed/30975169">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2146 href="https://doi.org/10.1186/s12974-019-1458-8">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6458787">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d3628e2159 class=n-a></a>Di Cesare Mannelli L, Pacini A, Micheli L, <i> et al.</i>: Glial role in oxaliplatin-induced neuropathic pain. <i>Exp Neurol.</i> 2014; <b>261</b>: 22–33. <a target=xrefwindow id=d3628e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/24967684">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2173 href="https://doi.org/10.1016/j.expneurol.2014.06.016">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d3628e2182 class=n-a></a>Hu LY, Zhou Y, Cui WQ, <i> et al.</i>: Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice. <i>Brain Behav Immun.</i> 2018; <b>68</b>: 132–45. <a target=xrefwindow id=d3628e2193 href="http://www.ncbi.nlm.nih.gov/pubmed/29051087">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2196 href="https://doi.org/10.1016/j.bbi.2017.10.011">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d3628e2205 class=n-a></a>Wu J, Hocevar M, Bie B, <i> et al.</i>: Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. <i>J Pain.</i> 2019; <b>20</b>(5): 501–14. <a target=xrefwindow id=d3628e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/30414958">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2219 href="https://doi.org/10.1016/j.jpain.2018.10.007">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d3628e2229 class=n-a></a>Zhang H, Yoon SY, Zhang H, <i> et al.</i>: Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. <i>J Pain.</i> 2012; <b>13</b>(3): 293–303. <a target=xrefwindow id=d3628e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/22285612">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2243 href="https://doi.org/10.1016/j.jpain.2011.12.002">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2247 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3294066">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d3628e2256 class=n-a></a>Robinson CR, Zhang H, Dougherty PM: Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. <i>Neuroscience.</i> 2014; <b>274</b>: 308–17. <a target=xrefwindow id=d3628e2264 href="http://www.ncbi.nlm.nih.gov/pubmed/24905437">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2267 href="https://doi.org/10.1016/j.neuroscience.2014.05.051">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4099296">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d3628e2279 class=n-a></a>Janes K, Wahlman C, Little JW, <i> et al.</i>: Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. <i>Brain Behav Immun.</i> 2015; <b>44</b>: 91–9. <a target=xrefwindow id=d3628e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/25220279">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2293 href="https://doi.org/10.1016/j.bbi.2014.08.010">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2297 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4275321">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d3628e2306 class=n-a></a>Wahlman C, Doyle TM, Little JW, <i> et al.</i>: Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. <i>Pain.</i> 2018; <b>159</b>(6): 1025–34. <a target=xrefwindow id=d3628e2317 href="http://www.ncbi.nlm.nih.gov/pubmed/29419652">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2320 href="https://doi.org/10.1097/j.pain.0000000000001177">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2324 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5955834">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d3628e2333 class=n-a></a>Janes K, Little JW, Li C, <i> et al.</i>: The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. <i>J Biol Chem.</i> 2014; <b>289</b>(30): 21082–97. <a target=xrefwindow id=d3628e2344 href="http://www.ncbi.nlm.nih.gov/pubmed/24876379">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2347 href="https://doi.org/10.1074/jbc.M114.569574">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4110312">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d3628e2360 class=n-a></a>Stockstill K, Doyle TM, Yan X, <i> et al.</i>: Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. <i>J Exp Med.</i> 2018; <b>215</b>(5): 1301–13. <a target=xrefwindow id=d3628e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/29703731">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2374 href="https://doi.org/10.1084/jem.20170584">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2378 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5940258">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d3628e2388 class=n-a></a>Mapplebeck JCS, Dalgarno R, Tu Y, <i> et al.</i>: Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. <i>Pain.</i> 2018; <b>159</b>(9): 1752–1763. <a target=xrefwindow id=d3628e2399 href="http://www.ncbi.nlm.nih.gov/pubmed/29927790">PubMed Abstract </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d3628e2408 class=n-a></a>Luo X, Huh Y, Bang S, <i> et al.</i>: Macrophage Toll-like Receptor 9 Contributes to Chemotherapy-Induced Neuropathic Pain in Male Mice. <i>J Neurosci.</i> 2019; <b>39</b>(35): 6848–64. <a target=xrefwindow id=d3628e2419 href="http://www.ncbi.nlm.nih.gov/pubmed/31270160">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2422 href="https://doi.org/10.1523/JNEUROSCI.3257-18.2019">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2426 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6733562">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d3628e2435 class=n-a></a>Zhang H, Li Y, de Carvalho-Barbosa M, <i> et al.</i>: Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. <i>J Pain.</i> 2016; <b>17</b>(7): 775–86. <a target=xrefwindow id=d3628e2446 href="http://www.ncbi.nlm.nih.gov/pubmed/26979998">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2449 href="https://doi.org/10.1016/j.jpain.2016.02.011">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2453 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4939513">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d3628e2462 class=n-a></a>Li Y, Zhang H, Zhang H, <i> et al.</i>: Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. <i>J Pain.</i> 2014; <b>15</b>(7): 712–25. <a target=xrefwindow id=d3628e2473 href="http://www.ncbi.nlm.nih.gov/pubmed/24755282">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2476 href="https://doi.org/10.1016/j.jpain.2014.04.001">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2480 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4083500">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d3628e2489 class=n-a></a>Liu CC, Lu N, Cui Y, <i> et al.</i>: Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. <i>Mol Pain.</i> 2010; <b>6</b>: 76. <a target=xrefwindow id=d3628e2500 href="http://www.ncbi.nlm.nih.gov/pubmed/21050491">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2503 href="https://doi.org/10.1186/1744-8069-6-76">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2991291">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d3628e2516 class=n-a></a>Pachman DR, Dockter T, Zekan PJ, <i> et al.</i>: A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. <i>Support Care Cancer.</i> 2017; <b>25</b>(11): 3407–16. <a target=xrefwindow id=d3628e2527 href="http://www.ncbi.nlm.nih.gov/pubmed/28551844">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2530 href="https://doi.org/10.1007/s00520-017-3760-2">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d3628e2540 class=n-a></a>Wang XS, Shi Q, Bhadkamkar NA, <i> et al.</i>: Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. <i>J Pain Symptom Manage.</i> 2019; <b>58</b>(4): 662–71. <a target=xrefwindow id=d3628e2551 href="http://www.ncbi.nlm.nih.gov/pubmed/31254639">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2554 href="https://doi.org/10.1016/j.jpainsymman.2019.06.018">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2558 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6754803">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d3628e2567 class=n-a></a>Tikka T, Fiebich BL, Goldsteins G, <i> et al.</i>: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. <i>J Neurosci.</i> 2001; <b>21</b>(8): 2580–8. <a target=xrefwindow id=d3628e2578 href="http://www.ncbi.nlm.nih.gov/pubmed/11306611">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2581 href="https://doi.org/10.1523/JNEUROSCI.21-08-02580.2001">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6762519">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d3628e2594 class=n-a></a>Yrjänheikki J, Tikka T, Keinänen R, <i> et al.</i>: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(23): 13496–500. <a target=xrefwindow id=d3628e2605 href="http://www.ncbi.nlm.nih.gov/pubmed/10557349">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2608 href="https://doi.org/10.1073/pnas.96.23.13496">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2612 href="http://www.ncbi.nlm.nih.gov/pmc/articles/23976">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d3628e2621 class=n-a></a>Aromolaran KA, Goldstein PA: Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? <i>Mol Pain.</i> 2017; <b>13</b>: 174480691771469. <a target=xrefwindow id=d3628e2629 href="http://www.ncbi.nlm.nih.gov/pubmed/28580836">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2632 href="https://doi.org/10.1177/1744806917714693">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2635 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5480635">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d3628e2644 class=n-a></a>Bennett DL, Clark AJ, Huang J, <i> et al.</i>: The Role of Voltage-Gated Sodium Channels in Pain Signaling. <i>Physiol Rev.</i> 2019; <b>99</b>(2): 1079–151. <a target=xrefwindow id=d3628e2655 href="http://www.ncbi.nlm.nih.gov/pubmed/30672368">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2658 href="https://doi.org/10.1152/physrev.00052.2017">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d3628e2667 class=n-a></a>Heide R, Bostock H, Ventzel L, <i> et al.</i>: Axonal excitability changes and acute symptoms of oxaliplatin treatment: <i>In vivo</i> evidence for slowed sodium channel inactivation. <i>Clin Neurophysiol.</i> 2018; <b>129</b>(3): 694–706. <a target=xrefwindow id=d3628e2681 href="http://www.ncbi.nlm.nih.gov/pubmed/29233604">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2685 href="https://doi.org/10.1016/j.clinph.2017.11.015">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d3628e2695 class=n-a></a>Argyriou AA, Cavaletti G, Antonacopoulou A, <i> et al.</i>: Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. <i>Cancer.</i> 2013; <b>119</b>(9): 3570–7. <a target=xrefwindow id=d3628e2706 href="http://www.ncbi.nlm.nih.gov/pubmed/23821303">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2709 href="https://doi.org/10.1002/cncr.28234">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d3628e2718 class=n-a></a>Li Y, North RY, Rhines LD, <i> et al.</i>: DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain. <i>J Neurosci.</i> 2018; <b>38</b>(5): 1124–36. <a target=xrefwindow id=d3628e2729 href="http://www.ncbi.nlm.nih.gov/pubmed/29255002">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2732 href="https://doi.org/10.1523/JNEUROSCI.0899-17.2017">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5792474">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d3628e2745 class=n-a></a>Descoeur J, Pereira V, Pizzoccaro A, <i> et al.</i>: Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. <i>EMBO Mol Med.</i> 2011; <b>3</b>(5): 266–78. <a target=xrefwindow id=d3628e2756 href="http://www.ncbi.nlm.nih.gov/pubmed/21438154">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2759 href="https://doi.org/10.1002/emmm.201100134">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3377073">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d3628e2772 class=n-a></a>Hershman DL, Lacchetti C, Dworkin RH, <i> et al.</i>: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2014; <b>32</b>(18): 1941–67. <a target=xrefwindow id=d3628e2783 href="http://www.ncbi.nlm.nih.gov/pubmed/24733808">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2786 href="https://doi.org/10.1200/JCO.2013.54.0914">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d3628e2795 class=n-a></a>Viatchenko-Karpinski V, Ling J, Gu JG: Down-regulation of Kv4.3 channels and a-type K<sup>+</sup> currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment. <i>Mol Pain.</i> 2018; <b>14</b>(14): 1744806917750995. <a target=xrefwindow id=d3628e2806 href="http://www.ncbi.nlm.nih.gov/pubmed/29313436">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2809 href="https://doi.org/10.1177/1744806917750995">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2813 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5764133">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d3628e2822 class=n-a></a>Poupon L, Lamoine S, Pereira V, <i> et al.</i>: Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. <i>Neuropharmacology.</i> 2018; <b>140</b>: 43–61. <a target=xrefwindow id=d3628e2833 href="http://www.ncbi.nlm.nih.gov/pubmed/30056126">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2836 href="https://doi.org/10.1016/j.neuropharm.2018.07.026">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d3628e2846 class=n-a></a>Kerckhove N, Busserolles J, Stanbury T, <i> et al.</i>: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. <i>BMJ Open.</i> 2019; <b>9</b>(6): e027770. <a target=xrefwindow id=d3628e2857 href="http://www.ncbi.nlm.nih.gov/pubmed/31182448">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2860 href="https://doi.org/10.1136/bmjopen-2018-027770">Publisher Full Text </a> | <a target=xrefwindow id=d3628e2864 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6561607">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d3628e2873 class=n-a></a>Chukyo A, Chiba T, Kambe T, <i> et al.</i>: Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. <i>Neuropeptides.</i> 2018; <b>67</b>: 95–101. <a target=xrefwindow id=d3628e2884 href="http://www.ncbi.nlm.nih.gov/pubmed/29274843">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2887 href="https://doi.org/10.1016/j.npep.2017.12.002">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d3628e2896 class=n-a></a>Rigo FK, Dalmolin GD, Trevisan G, <i> et al.</i>: Effect of ω-conotoxin MVIIA and Phα1β on paclitaxel-induced acute and chronic pain. <i>Pharmacol Biochem Behav.</i> 2013; <b>114–115</b>: 16–22. <a target=xrefwindow id=d3628e2907 href="http://www.ncbi.nlm.nih.gov/pubmed/24148893">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2910 href="https://doi.org/10.1016/j.pbb.2013.10.014">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d3628e2919 class=n-a></a>Flatters SJ, Bennett GJ: Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. <i>Pain.</i> 2004; <b>109</b>(1–2): 150–61. <a target=xrefwindow id=d3628e2927 href="http://www.ncbi.nlm.nih.gov/pubmed/15082137">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2930 href="https://doi.org/10.1016/j.pain.2004.01.029">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d3628e2939 class=n-a></a>Dolphin AC: Calcium channel auxiliary α<sub>2</sub>δ and β subunits: trafficking and one step beyond. <i>Nat Rev Neurosci.</i> 2012; <b>13</b>(8): 542–55. <a target=xrefwindow id=d3628e2950 href="http://www.ncbi.nlm.nih.gov/pubmed/22805911">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2953 href="https://doi.org/10.1038/nrn3311">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d3628e2962 class=n-a></a>Han FY, Kuo A, Nicholson JR, <i> et al.</i>: Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy. <i>Clin Exp Pharmacol Physiol.</i> 2018; <b>45</b>(10): 1067–75. <a target=xrefwindow id=d3628e2973 href="http://www.ncbi.nlm.nih.gov/pubmed/29781509">PubMed Abstract </a> | <a target=xrefwindow id=d3628e2976 href="https://doi.org/10.1111/1440-1681.12971">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d3628e2986 class=n-a></a>Shahid M, Subhan F, Ahmad N, <i> et al.</i>: Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. <i>BMC Pharmacol Toxicol.</i> 2019; <b>20</b>(1): 51. <a target=xrefwindow id=d3628e2997 href="http://www.ncbi.nlm.nih.gov/pubmed/31462283">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3000 href="https://doi.org/10.1186/s40360-019-0329-3">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6714310">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d3628e3013 class=n-a></a>de Andrade DC, Jacobsen Teixeira M, Galhardoni R, <i> et al.</i>: Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. <i>Oncologist.</i> 2017; <b>22</b>(10): 1154–e105. <a target=xrefwindow id=d3628e3024 href="http://www.ncbi.nlm.nih.gov/pubmed/28652279">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3027 href="https://doi.org/10.1634/theoncologist.2017-0235">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3031 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5634769">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d3628e3040 class=n-a></a>Hershman DL, Till C, Wright JD, <i> et al.</i>: Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>J Clin Oncol.</i> 2016; <b>34</b>(25): 3014–22. <a target=xrefwindow id=d3628e3051 href="http://www.ncbi.nlm.nih.gov/pubmed/27325863">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3054 href="https://doi.org/10.1200/JCO.2015.66.2346">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3058 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5012713">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d3628e3067 class=n-a></a>Uwah AN, Ackler J, Leighton JC Jr, <i> et al.</i>: The effect of diabetes on oxaliplatin-induced peripheral neuropathy. <i>Clin Colorectal Cancer.</i> 2012; <b>11</b>(4): 275–9. <a target=xrefwindow id=d3628e3078 href="http://www.ncbi.nlm.nih.gov/pubmed/22682776">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3081 href="https://doi.org/10.1016/j.clcc.2012.05.002">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d3628e3090 class=n-a></a>Vincenzi B, Frezza AM, Schiavon G, <i> et al.</i>: Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. <i>Support Care Cancer.</i> 2013; <b>21</b>(5): 1313–9. <a target=xrefwindow id=d3628e3101 href="http://www.ncbi.nlm.nih.gov/pubmed/23196819">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3104 href="https://doi.org/10.1007/s00520-012-1667-5">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d3628e3113 class=n-a></a>Argyriou AA, Iconomou G, Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. <i>Blood.</i> 2008; <b>112</b>(5): 1593–9. <a target=xrefwindow id=d3628e3121 href="http://www.ncbi.nlm.nih.gov/pubmed/18574024">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3124 href="https://doi.org/10.1182/blood-2008-04-149385">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d3628e3134 class=n-a></a>Argyriou AA, Bruna J, Genazzani AA, <i> et al.</i>: Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. <i>Nat Rev Neurol.</i> 2017; <b>13</b>(8): 492–504. <a target=xrefwindow id=d3628e3145 href="http://www.ncbi.nlm.nih.gov/pubmed/28664909">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3148 href="https://doi.org/10.1038/nrneurol.2017.88">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d3628e3157 class=n-a></a>Caraceni A, Cherny N, Fainsinger R, <i> et al.</i>: Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. <i>J Pain Symptom Manage.</i> 2002; <b>23</b>(3): 239–55. <a target=xrefwindow id=d3628e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/11888722">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3171 href="https://doi.org/10.1016/s0885-3924(01)00409-2">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d3628e3180 class=n-a></a>Bennett M: The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. <i>Pain.</i> 2001; <b>92</b>(1–2): 147–57. <a target=xrefwindow id=d3628e3188 href="http://www.ncbi.nlm.nih.gov/pubmed/11323136">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3191 href="https://doi.org/10.1016/s0304-3959(00)00482-6">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d3628e3200 class=n-a></a>Bouhassira D, Attal N, Alchaar H, <i> et al.</i>: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). <i>Pain.</i> 2005; <b>114</b>(1–2): 29–36. <a target=xrefwindow id=d3628e3211 href="http://www.ncbi.nlm.nih.gov/pubmed/15733628">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3214 href="https://doi.org/10.1016/j.pain.2004.12.010">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d3628e3223 class=n-a></a>Sandier SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. <i>Neurology.</i> 1969; <b>19</b>(4): 367. <a target=xrefwindow id=d3628e3231 href="http://www.ncbi.nlm.nih.gov/pubmed/5813374">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3234 href="https://doi.org/10.1212/wnl.19.4.367">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d3628e3243 class=n-a></a>Kandula T, Park SB, Cohn RJ, <i> et al.</i>: Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. <i>Cancer Treat Rev.</i> 2016; <b>50</b>: 118–28. <a target=xrefwindow id=d3628e3254 href="http://www.ncbi.nlm.nih.gov/pubmed/27664395">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3257 href="https://doi.org/10.1016/j.ctrv.2016.09.005">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d3628e3267 class=n-a></a>Lavoie Smith EM, Li L, Hutchinson RJ, <i> et al.</i>: Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. <i>Cancer Nurs.</i> 2013; <b>36</b>(5): E49–E60. <a target=xrefwindow id=d3628e3278 href="http://www.ncbi.nlm.nih.gov/pubmed/23842524">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3281 href="https://doi.org/10.1097/NCC.0b013e318299ad23">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3951303">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d3628e3294 class=n-a></a>McGrath PJ, Walco GA, Turk DC, <i> et al.</i>: Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. <i>J Pain.</i> 2008; <b>9</b>(9): 771–83. <a target=xrefwindow id=d3628e3305 href="http://www.ncbi.nlm.nih.gov/pubmed/18562251">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3308 href="https://doi.org/10.1016/j.jpain.2008.04.007">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d3628e3317 class=n-a></a>Postma TJ, Heimans JJ, Muller MJ, <i> et al.</i>: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. <i>Ann Oncol.</i> 1998; <b>9</b>(7): 739–44. <a target=xrefwindow id=d3628e3328 href="http://www.ncbi.nlm.nih.gov/pubmed/9739440">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3331 href="https://doi.org/10.1023/a:1008344507482">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d3628e3340 class=n-a></a>Shimozuma K, Ohashi Y, Takeuchi A, <i> et al.</i>: Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. <i>Support Care Cancer.</i> 2009; <b>17</b>(12): 1483–91. <a target=xrefwindow id=d3628e3351 href="http://www.ncbi.nlm.nih.gov/pubmed/19330359">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3354 href="https://doi.org/10.1007/s00520-009-0613-7">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d3628e3363 class=n-a></a>Haryani H, Fetzer SJ, Wu CL, <i> et al.</i>: Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. <i>Oncol Nurs Forum.</i> 2017; <b>44</b>(3): E111–E123. <a target=xrefwindow id=d3628e3374 href="http://www.ncbi.nlm.nih.gov/pubmed/28635977">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3377 href="https://doi.org/10.1188/17.ONF.E111-E123">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d3628e3386 class=n-a></a>McCrary JM, Goldstein D, Boyle F, <i> et al.</i>: Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Support Care Cancer.</i> 2017; <b>25</b>(11): 3485–93. <a target=xrefwindow id=d3628e3397 href="http://www.ncbi.nlm.nih.gov/pubmed/28589310">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3400 href="https://doi.org/10.1007/s00520-017-3772-y">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d3628e3410 class=n-a></a>Calhoun EA, Welshman EE, Chang CH, <i> et al.</i>: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. <i>Int J Gynecol Cancer.</i> 2003; <b>13</b>(6): 741–8. <a target=xrefwindow id=d3628e3421 href="http://www.ncbi.nlm.nih.gov/pubmed/14675309">PubMed Abstract </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d3628e3430 class=n-a></a>Huang HQ, Brady MF, Cella D, <i> et al.</i>: Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. <i>Int J Gynecol Cancer.</i> 2007; <b>17</b>(2): 387–93. <a target=xrefwindow id=d3628e3441 href="http://www.ncbi.nlm.nih.gov/pubmed/17362317">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3444 href="https://doi.org/10.1111/j.1525-1438.2007.00794.x">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d3628e3453 class=n-a></a>Cavaletti G, Frigeni B, Lanzani F, <i> et al.</i>: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. <i>J Peripher Nerv Syst.</i> 2007; <b>12</b>(3): 210–5. <a target=xrefwindow id=d3628e3464 href="http://www.ncbi.nlm.nih.gov/pubmed/17868248">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3467 href="https://doi.org/10.1111/j.1529-8027.2007.00141.x">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d3628e3476 class=n-a></a>Cavaletti G, Cornblath DR, Merkies IS, <i> et al.</i>: The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Ann Oncol.</i> 2013; <b>24</b>(2): 454–62. <a target=xrefwindow id=d3628e3487 href="http://www.ncbi.nlm.nih.gov/pubmed/22910842">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3490 href="https://doi.org/10.1093/annonc/mds329">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3494 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3551481">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d3628e3503 class=n-a></a>Postma TJ, Aaronson NK, Heimans JJ, <i> et al.</i>: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. <i>Eur J Cancer.</i> 2005; <b>41</b>(8): 1135–9. <a target=xrefwindow id=d3628e3514 href="http://www.ncbi.nlm.nih.gov/pubmed/15911236">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3517 href="https://doi.org/10.1016/j.ejca.2005.02.012">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d3628e3526 class=n-a></a>Thompson SW, Davis LE, Kornfeld M, <i> et al.</i>: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. <i>Cancer.</i> 1984; <b>54</b>(7): 1269–75. <a target=xrefwindow id=d3628e3537 href="http://www.ncbi.nlm.nih.gov/pubmed/6088023">PubMed Abstract </a> | <a target="xrefwindow" id="d3628e3540" href="https://doi.org/10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707&gt;3.0.co;2-9">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d3628e3550 class=n-a></a>Rowinsky EK, Chaudhry V, Cornblath DR, <i> et al.</i>: Neurotoxicity of Taxol. <i>J Natl Cancer Inst Monogr.</i> 1993; (15): 107–15. <a target=xrefwindow id=d3628e3558 href="http://www.ncbi.nlm.nih.gov/pubmed/7912516">PubMed Abstract </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d3628e3567 class=n-a></a>Maier C, Baron R, Tölle TR, <i> et al.</i>: Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. <i>Pain.</i> 2010; <b>150</b>(3): 439–50. <a target=xrefwindow id=d3628e3578 href="http://www.ncbi.nlm.nih.gov/pubmed/20627413">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3581 href="https://doi.org/10.1016/j.pain.2010.05.002">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d3628e3590 class=n-a></a>Zhi WI, Chen P, Kwon A, <i> et al.</i>: Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. <i>Breast Cancer Res Treat.</i> 2019; <b>178</b>(3): 587–95. <a target=xrefwindow id=d3628e3601 href="http://www.ncbi.nlm.nih.gov/pubmed/31456070">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3604 href="https://doi.org/10.1007/s10549-019-05416-4">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3608 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6819268">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d3628e3617 class=n-a></a>Dougherty PM, Cata JP, Cordella JV, <i> et al.</i>: Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. <i>Pain.</i> 2004; <b>109</b>(1–2): 132–42. <a target=xrefwindow id=d3628e3628 href="http://www.ncbi.nlm.nih.gov/pubmed/15082135">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3631 href="https://doi.org/10.1016/j.pain.2004.01.021">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d3628e3640 class=n-a></a>Cata JP, Weng HR, Burton AW, <i> et al.</i>: Quantitative sensory findings in patients with bortezomib-induced pain. <i>J Pain.</i> 2007; <b>8</b>(4): 296–306. <a target=xrefwindow id=d3628e3651 href="http://www.ncbi.nlm.nih.gov/pubmed/17175202">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3654 href="https://doi.org/10.1016/j.jpain.2006.09.014">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d3628e3663 class=n-a></a>Dougherty PM, Cata JP, Burton AW, <i> et al.</i>: Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. <i>J Pain Symptom Manage.</i> 2007; <b>33</b>(2): 166–79. <a target=xrefwindow id=d3628e3674 href="http://www.ncbi.nlm.nih.gov/pubmed/17280922">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3677 href="https://doi.org/10.1016/j.jpainsymman.2006.08.006">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d3628e3687 class=n-a></a>Wang XS, Shi Q, Dougherty PM, <i> et al.</i>: Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. <i>Oncology.</i> 2016; <b>90</b>(3): 127–35. <a target=xrefwindow id=d3628e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/26882477">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3701 href="https://doi.org/10.1159/000443377">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3705 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4794365">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d3628e3714 class=n-a></a>Roldan CJ, Johnson C, Lee SO, <i> et al.</i>: Subclinical Peripheral Neuropathy in Patients with Head and Neck Cancer: A Quantitative Sensory Testing (QST) Study. <i>Pain Physician.</i> 2018; <b>21</b>(4): E419–E427. <a target=xrefwindow id=d3628e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/30045608">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3728 href="https://doi.org/10.36076/ppj.2018.4.E419">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6471511">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d3628e3741 class=n-a></a>Ventzel L, Madsen CS, Karlsson P, <i> et al.</i>: Chronic Pain and Neuropathy Following Adjuvant Chemotherapy. <i>Pain Med.</i> 2018; <b>19</b>(9): 1813–24. <a target=xrefwindow id=d3628e3752 href="http://www.ncbi.nlm.nih.gov/pubmed/29036361">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3755 href="https://doi.org/10.1093/pm/pnx231">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d3628e3764 class=n-a></a>Forstenpointner J, Oberlojer VC, Naleschinski D, <i> et al.</i>: A-Fibers Mediate Cold Hyperalgesia in Patients with Oxaliplatin-Induced Neuropathy. <i>Pain Pract.</i> 2018; <b>18</b>(6): 758–67. <a target=xrefwindow id=d3628e3775 href="http://www.ncbi.nlm.nih.gov/pubmed/29222932">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3778 href="https://doi.org/10.1111/papr.12670">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d3628e3787 class=n-a></a>Geber C, Breimhorst M, Burbach B, <i> et al.</i>: Pain in chemotherapy-induced neuropathy–more than neuropathic? <i>Pain.</i> 2013; <b>154</b>(12): 2877–87. <a target=xrefwindow id=d3628e3798 href="http://www.ncbi.nlm.nih.gov/pubmed/23999056">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3801 href="https://doi.org/10.1016/j.pain.2013.08.028">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d3628e3810 class=n-a></a>Delmotte JB, Beaussier H, Auzeil N, <i> et al.</i>: Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study. <i>Cancer Treat Res Commun.</i> 2018; <b>17</b>: 31–6. <a target=xrefwindow id=d3628e3821 href="http://www.ncbi.nlm.nih.gov/pubmed/30343217">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3824 href="https://doi.org/10.1016/j.ctarc.2018.10.002">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d3628e3834 class=n-a></a>Mangus LM, Rao DB, Ebenezer GJ: Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review. <i>Toxicol Pathol.</i> 2020; <b>48</b>(1): 59–70. <a target=xrefwindow id=d3628e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/31221022">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3845 href="https://doi.org/10.1177/0192623319855969">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d3628e3854 class=n-a></a>Krøigård T, Svendsen TK, Wirenfeldt M, <i> et al.</i>: Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy-induced polyneuropathy symptoms and signs. <i>Eur J Neurol.</i> 2020; <b>27</b>(1): 68–76. <a target=xrefwindow id=d3628e3865 href="http://www.ncbi.nlm.nih.gov/pubmed/31373417">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3868 href="https://doi.org/10.1111/ene.14035">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d3628e3877 class=n-a></a>Burakgazi AZ, Messersmith W, Vaidya D, <i> et al.</i>: Longitudinal assessment of oxaliplatin-induced neuropathy. <i>Neurology.</i> 2011; <b>77</b>(10): 980–6. <a target=xrefwindow id=d3628e3888 href="http://www.ncbi.nlm.nih.gov/pubmed/21865571">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3891 href="https://doi.org/10.1212/WNL.0b013e31822cfc59">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3895 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3171958">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d3628e3904 class=n-a></a>Richardson PG, Xie W, Mitsiades C, <i> et al.</i>: Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>J Clin Oncol.</i> 2009; <b>27</b>(21): 3518–25. <a target=xrefwindow id=d3628e3915 href="http://www.ncbi.nlm.nih.gov/pubmed/19528374">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3918 href="https://doi.org/10.1200/JCO.2008.18.3087">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3922 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2717758">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d3628e3931 class=n-a></a>Koskinen MJ, Kautio AL, Haanpää ML, <i> et al.</i>: Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. <i>Anticancer Res.</i> 2011; <b>31</b>(12): 4413–6. <a target=xrefwindow id=d3628e3942 href="http://www.ncbi.nlm.nih.gov/pubmed/22199308">PubMed Abstract </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d3628e3951 class=n-a></a>Griffith KA, Dorsey SG, Renn CL, <i> et al.</i>: Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. <i>J Peripher Nerv Syst.</i> 2014; <b>19</b>(2): 127–35. <a target=xrefwindow id=d3628e3962 href="http://www.ncbi.nlm.nih.gov/pubmed/24814100">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3965 href="https://doi.org/10.1111/jns5.12064">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4175057">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d3628e3979 class=n-a></a>Hanai A, Ishiguro H, Sozu T, <i> et al.</i>: Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. <i>J Natl Cancer Inst.</i> 2018; <b>110</b>(2): 141–8. <a target=xrefwindow id=d3628e3990 href="http://www.ncbi.nlm.nih.gov/pubmed/29924336">PubMed Abstract </a> | <a target=xrefwindow id=d3628e3993 href="https://doi.org/10.1093/jnci/djx178">Publisher Full Text </a> | <a target=xrefwindow id=d3628e3997 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6007752">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d3628e4006 class=n-a></a>Griffiths C, Kwon N, Beaumont JL, <i> et al.</i>: Cold therapy to prevent paclitaxel-induced peripheral neuropathy. <i>Support Care Cancer.</i> 2018; <b>26</b>(10): 3461–9. <a target=xrefwindow id=d3628e4017 href="http://www.ncbi.nlm.nih.gov/pubmed/29681015">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4020 href="https://doi.org/10.1007/s00520-018-4199-9">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d3628e4029 class=n-a></a>Ruddy KJ, Le-Rademacher J, Lacouture ME, <i> et al.</i>: Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. <i>Breast.</i> 2019; <b>48</b>: 89–97. <a target=xrefwindow id=d3628e4040 href="http://www.ncbi.nlm.nih.gov/pubmed/31590108">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4043 href="https://doi.org/10.1016/j.breast.2019.09.011">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d3628e4052 class=n-a></a>Sundar R, Bandla A, Tan SS, <i> et al.</i>: Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. <i>Front Oncol.</i> 2017; <b>6</b>: 274. <a target=xrefwindow id=d3628e4063 href="http://www.ncbi.nlm.nih.gov/pubmed/28119855">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4066 href="https://doi.org/10.3389/fonc.2016.00274">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4070 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5222823">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d3628e4079 class=n-a></a>Smith EM, Pang H, Cirrincione C, <i> et al.</i>: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. <i>JAMA.</i> 2013; <b>309</b>(13): 1359. <a target=xrefwindow id=d3628e4090 href="http://www.ncbi.nlm.nih.gov/pubmed/23549581">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4093 href="https://doi.org/10.1001/jama.2013.2813">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4097 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3912515">Free Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d3628e4106 class=n-a></a>Gewandter JS, Dworkin RH, Finnerup NB, <i> et al.</i>: Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology? <i>Pain.</i> 2017; <b>158</b>(1): 30–3. <a target=xrefwindow id=d3628e4117 href="http://www.ncbi.nlm.nih.gov/pubmed/27564867">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4120 href="https://doi.org/10.1097/j.pain.0000000000000653">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4124 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6784316">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d3628e4134 class=n-a></a>Dworkin RH, Turk DC, Farrar JT, <i> et al.</i>: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. <i>Pain.</i> 2005; <b>113</b>(1–2): 9–19. <a target=xrefwindow id=d3628e4145 href="http://www.ncbi.nlm.nih.gov/pubmed/15621359">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4148 href="https://doi.org/10.1016/j.pain.2004.09.012">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d3628e4157 class=n-a></a>Farshchian N, Alavi A, Heydarheydari S, <i> et al.</i>: Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. <i>Cancer Chemother Pharmacol.</i> 2018; <b>82</b>(5): 787–93. <a target=xrefwindow id=d3628e4168 href="http://www.ncbi.nlm.nih.gov/pubmed/30105459">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4171 href="https://doi.org/10.1007/s00280-018-3664-y">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d3628e4180 class=n-a></a>Demant DT, Lund K, Vollert J, <i> et al.</i>: The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. <i>Pain.</i> 2014; <b>155</b>(11): 2263–73. <a target=xrefwindow id=d3628e4191 href="http://www.ncbi.nlm.nih.gov/pubmed/25139589">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4194 href="https://doi.org/10.1016/j.pain.2014.08.014">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d3628e4203 class=n-a></a>Attal N, Rouaud J, Brasseur L, <i> et al.</i>: Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. <i>Neurology.</i> 2004; <b>62</b>(2): 218–25. <a target=xrefwindow id=d3628e4214 href="http://www.ncbi.nlm.nih.gov/pubmed/14745057">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4217 href="https://doi.org/10.1212/01.wnl.0000103237.62009.77">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d3628e4226 class=n-a></a>Finnerup NB, Sindrup SH, Bach FW, <i> et al.</i>: Lamotrigine in spinal cord injury pain: a randomized controlled trial. <i>Pain.</i> 2002; <b>96</b>(3): 375–83. <a target=xrefwindow id=d3628e4237 href="http://www.ncbi.nlm.nih.gov/pubmed/11973012">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4240 href="https://doi.org/10.1016/s0304-3959(01)00484-5">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d3628e4249 class=n-a></a>Mainka T, Malewicz NM, Baron R, <i> et al.</i>: Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. <i>Eur J Pain.</i> 2016; <b>20</b>(1): 116–29. <a target=xrefwindow id=d3628e4260 href="http://www.ncbi.nlm.nih.gov/pubmed/25854794">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4263 href="https://doi.org/10.1002/ejp.703">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d3628e4273 class=n-a></a>Fallon MT, Storey DJ, Krishan A, <i> et al.</i>: Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. <i>Support Care Cancer.</i> 2015; <b>23</b>(9): 2769–77. <a target=xrefwindow id=d3628e4284 href="http://www.ncbi.nlm.nih.gov/pubmed/25680765">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4287 href="https://doi.org/10.1007/s00520-015-2642-8">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4291 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4519585">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d3628e4300 class=n-a></a>Barton DL, Wos EJ, Qin R, <i> et al.</i>: A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. <i>Support Care Cancer.</i> 2011; <b>19</b>(6): 833–41. <a target=xrefwindow id=d3628e4311 href="http://www.ncbi.nlm.nih.gov/pubmed/20496177">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4314 href="https://doi.org/10.1007/s00520-010-0911-0">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3338170">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d3628e4327 class=n-a></a>Anand P, Elsafa E, Privitera R, <i> et al.</i>: Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. <i>J Pain Res.</i> 2019; <b>12</b>: 2039–52. <a target=xrefwindow id=d3628e4338 href="http://www.ncbi.nlm.nih.gov/pubmed/31308732">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4341 href="https://doi.org/10.2147/JPR.S213912">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4345 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6613356">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d3628e4354 class=n-a></a>Mulpuri Y, Marty VN, Munier JJ, <i> et al.</i>: Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. <i>Neuropharmacology.</i> 2018; <b>139</b>: 85–97. <a target=xrefwindow id=d3628e4365 href="http://www.ncbi.nlm.nih.gov/pubmed/29981335">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4368 href="https://doi.org/10.1016/j.neuropharm.2018.07.002">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4372 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6883926">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d3628e4381 class=n-a></a>Brenneman DE, Kinney WA, Ward SJ: Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity. <i>J Mol Neurosci.</i> 2019; <b>68</b>(4): 603–19. <a target=xrefwindow id=d3628e4389 href="http://www.ncbi.nlm.nih.gov/pubmed/31077084">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4392 href="https://doi.org/10.1007/s12031-019-01321-z">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4395 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6615992">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d3628e4404 class=n-a></a>Sierra S, Gupta A, Gomes I, <i> et al.</i>: Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain. <i>ACS Pharmacol Transl Sci.</i> 2019; <b>2</b>(4): 219–29. <a target=xrefwindow id=d3628e4415 href="http://www.ncbi.nlm.nih.gov/pubmed/31565698">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4418 href="https://doi.org/10.1021/acsptsci.9b00008">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6764458">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d3628e4432 class=n-a></a>King KM, Myers AM, Soroka-Monzo AJ, <i> et al.</i>: Single and combined effects of Δ<sup>9</sup> -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. <i>Br J Pharmacol.</i> 2017; <b>174</b>(17): 2832–41. <a target=xrefwindow id=d3628e4446 href="http://www.ncbi.nlm.nih.gov/pubmed/28548225">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4450 href="https://doi.org/10.1111/bph.13887">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4453 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5554313">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d3628e4462 class=n-a></a>Blanton HL, Brelsfoard J, DeTurk N, <i> et al.</i>: Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. <i>Drugs.</i> 2019; <b>79</b>(9): 969–95. <a target=xrefwindow id=d3628e4473 href="http://www.ncbi.nlm.nih.gov/pubmed/31127530">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4476 href="https://doi.org/10.1007/s40265-019-01132-x">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d3628e4485 class=n-a></a>Lynch ME, Cesar-Rittenberg P, Hohmann AG: A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. <i>J Pain Symptom Manage.</i> 2014; <b>47</b>(1): 166–73. <a target=xrefwindow id=d3628e4493 href="http://www.ncbi.nlm.nih.gov/pubmed/23742737">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4496 href="https://doi.org/10.1016/j.jpainsymman.2013.02.018">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d3628e4505 class=n-a></a>Finnerup NB, Attal N, Haroutounian S, <i> et al.</i>: Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurol.</i> 2015; <b>14</b>(2): 162–73. <a target=xrefwindow id=d3628e4516 href="http://www.ncbi.nlm.nih.gov/pubmed/25575710">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4519 href="https://doi.org/10.1016/S1474-4422(14)70251-0">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4523 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4493167">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d3628e4532 class=n-a></a>Hofmeister M, Memedovich A, Brown S, <i> et al.</i>: Effectiveness of Neurostimulation Technologies for the Management of Chronic Pain: A Systematic Review. <i>Neuromodulation.</i> 2020; <b>23</b>(2): 150–157. <a target=xrefwindow id=d3628e4543 href="http://www.ncbi.nlm.nih.gov/pubmed/31310417">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4546 href="https://doi.org/10.1111/ner.13020">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d3628e4555 class=n-a></a>Groenen PS, van Helmond N, Chapman KB: Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation. <i>Pain Med.</i> 2019; <b>20</b>(4): 857–9. <a target=xrefwindow id=d3628e4563 href="http://www.ncbi.nlm.nih.gov/pubmed/30412243">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4566 href="https://doi.org/10.1093/pm/pny209">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d3628e4576 class=n-a></a>Abd-Elsayed A, Schiavoni N, Sachdeva H: Efficacy of spinal cord stimulators in treating peripheral neuropathy: a case series. <i>J Clin Anesth.</i> 2016; <b>28</b>: 74–7. <a target=xrefwindow id=d3628e4584 href="http://www.ncbi.nlm.nih.gov/pubmed/26395919">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4587 href="https://doi.org/10.1016/j.jclinane.2015.08.011">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d3628e4596 class=n-a></a>Gewandter JS, Chaudari J, Ibegbu C, <i> et al.</i>: Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. <i>Support Care Cancer.</i> 2019; <b>27</b>(5): 1765–74. <a target=xrefwindow id=d3628e4607 href="http://www.ncbi.nlm.nih.gov/pubmed/30151681">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4610 href="https://doi.org/10.1007/s00520-018-4424-6">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6393221">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d3628e4623 class=n-a></a>Loprinzi C, Le-Rademacher JG, Majithia N, <i> et al.</i>: Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. <i>Support Care Cancer.</i> 2020; <b>28</b>(3): 1183–97. <a target=xrefwindow id=d3628e4634 href="http://www.ncbi.nlm.nih.gov/pubmed/31209630">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4637 href="https://doi.org/10.1007/s00520-019-04881-3">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d3628e4646 class=n-a></a>Smith TJ, Razzak AR, Blackford AL, <i> et al.</i>: A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). <i>J Palliat Care.</i> 2020; <b>35</b>(1): 53–8. <a target=xrefwindow id=d3628e4657 href="http://www.ncbi.nlm.nih.gov/pubmed/30714486">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4660 href="https://doi.org/10.1177/0825859719827589">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d3628e4669 class=n-a></a>Paley CA, Johnson MI, Tashani OA, <i> et al.</i>: Acupuncture for cancer pain in adults. <i>Cochrane Database Syst Rev.</i> 2015; (10): CD007753. <a target=xrefwindow id=d3628e4677 href="http://www.ncbi.nlm.nih.gov/pubmed/26468973">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4680 href="https://doi.org/10.1002/14651858.CD007753.pub3">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4683 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6513493">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d3628e4692 class=n-a></a>Jeong YJ, Kwak MA, Seo JC, <i> et al.</i>: Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Trial. <i>Evid Based Complement Alternat Med.</i> 2018; <b>2018</b>: 1–11. <a target=xrefwindow id=d3628e4703 href="http://www.ncbi.nlm.nih.gov/pubmed/30420895">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4706 href="https://doi.org/10.1155/2018/5367014">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6215569">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d3628e4720 class=n-a></a>Zhi WI, Ingram E, Li SQ, <i> et al.</i>: Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain. <i>Integr Cancer Ther.</i> 2018; <b>17</b>(4): 1079–86. <a target=xrefwindow id=d3628e4731 href="http://www.ncbi.nlm.nih.gov/pubmed/30027756">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4734 href="https://doi.org/10.1177/1534735418788667">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4738 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6247555">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d3628e4747 class=n-a></a>Molassiotis A, Suen LKP, Cheng HL, <i> et al.</i>: A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. <i>Integr Cancer Ther.</i> 2019; <b>18</b>: 1534735419836501. <a target=xrefwindow id=d3628e4758 href="http://www.ncbi.nlm.nih.gov/pubmed/30905173">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4761 href="https://doi.org/10.1177/1534735419836501">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6434440">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d3628e4774 class=n-a></a>Li K, Giustini D, Seely D: A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy. <i>Curr Oncol.</i> 2019; <b>26</b>(2): e147–e154. <a target=xrefwindow id=d3628e4782 href="http://www.ncbi.nlm.nih.gov/pubmed/31043820">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4785 href="https://doi.org/10.3747/co.26.4261">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6476456">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d3628e4797 class=n-a></a>Zimmer P, Trebing S, Timmers-Trebing U, <i> et al.</i>: Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. <i>Support Care Cancer.</i> 2018; <b>26</b>(2): 615–24. <a target=xrefwindow id=d3628e4808 href="http://www.ncbi.nlm.nih.gov/pubmed/28963591">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4811 href="https://doi.org/10.1007/s00520-017-3875-5">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d3628e4820 class=n-a></a>Duregon F, Vendramin B, Bullo V, <i> et al.</i>: Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review. <i>Crit Rev Oncol Hematol.</i> 2018; <b>121</b>: 90–100. <a target=xrefwindow id=d3628e4831 href="http://www.ncbi.nlm.nih.gov/pubmed/29198853">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4834 href="https://doi.org/10.1016/j.critrevonc.2017.11.002">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d3628e4843 class=n-a></a>Kleckner IR, Kamen C, Gewandter JS, <i> et al.</i>: Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. <i>Support Care Cancer.</i> 2018; <b>26</b>(4): 1019–28. <a target=xrefwindow id=d3628e4854 href="http://www.ncbi.nlm.nih.gov/pubmed/29243164">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4857 href="https://doi.org/10.1007/s00520-017-4013-0">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5823751">Free Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d3628e4871 class=n-a></a>van Waart H, Stuiver MM, van Harten WH, <i> et al.</i>: Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(17): 1918–27. <a target=xrefwindow id=d3628e4882 href="http://www.ncbi.nlm.nih.gov/pubmed/25918291">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4885 href="https://doi.org/10.1200/JCO.2014.59.1081">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d3628e4894 class=n-a></a>Mundal I, Gråwe RW, Bjørngaard JH, <i> et al.</i>: Psychosocial factors and risk of chronic widespread pain: an 11-year follow-up study--the HUNT study. <i>Pain.</i> 2014; <b>155</b>(8): 1555–61. <a target=xrefwindow id=d3628e4905 href="http://www.ncbi.nlm.nih.gov/pubmed/24813831">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4908 href="https://doi.org/10.1016/j.pain.2014.04.033">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d3628e4917 class=n-a></a>Lee KM, Jung D, Hwang H, <i> et al.</i>: Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. <i>J Psychosom Res.</i> 2018; <b>108</b>: 14–9. <a target=xrefwindow id=d3628e4928 href="http://www.ncbi.nlm.nih.gov/pubmed/29602320">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4931 href="https://doi.org/10.1016/j.jpsychores.2018.02.012">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d3628e4940 class=n-a></a>Knoerl R, Smith EML, Barton DL, <i> et al.</i>: Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial. <i>J Pain.</i> 2018; <b>19</b>(4): 382–94. <a target=xrefwindow id=d3628e4951 href="http://www.ncbi.nlm.nih.gov/pubmed/29229430">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4954 href="https://doi.org/10.1016/j.jpain.2017.11.009">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d3628e4963 class=n-a></a>Knoerl R, Barton DL, Holden JE, <i> et al.</i>: Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention. <i>Can Oncol Nurs J.</i> 2018; <b>28</b>(3): 178–83. <a target=xrefwindow id=d3628e4974 href="http://www.ncbi.nlm.nih.gov/pubmed/31148833">PubMed Abstract </a> | <a target=xrefwindow id=d3628e4977 href="https://doi.org/10.5737/23688076283178183">Publisher Full Text </a> | <a target=xrefwindow id=d3628e4981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6516921">Free Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d3628e4990 class=n-a></a>Bruna J, Videla S, Argyriou AA, <i> et al.</i>: Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics.</i> 2018; <b>15</b>(1): 178–89. <a target=xrefwindow id=d3628e5001 href="http://www.ncbi.nlm.nih.gov/pubmed/28924870">PubMed Abstract </a> | <a target=xrefwindow id=d3628e5004 href="https://doi.org/10.1007/s13311-017-0572-5">Publisher Full Text </a> | <a target=xrefwindow id=d3628e5008 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5794691">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-177/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-177/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK<br/> <p> <div class=margin-bottom> Richard Gordon-Williams <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Paul Farquhar-Smith <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-177/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 11 Mar 2020, 9:177 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21625.1">https://doi.org/10.12688/f1000research.21625.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Gordon-Williams R and Farquhar-Smith P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23837 data-id=21625 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21625.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-177/v1/pdf?article_uuid=578606ea-9afd-479d-bd7a-71c6826df8bc" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21625.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):177 (<a href="https://doi.org/10.12688/f1000research.21625.1" target=_blank>https://doi.org/10.12688/f1000research.21625.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21625 id=mobile-track-article-signin-21625 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21625?target=/articles/9-177/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23837 /> <input name=articleId type=hidden value=21625 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Irina Vetter</strong>, Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Peter M. Grace</strong>, Department of Symptom Research, University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-177/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-177/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64372-60342></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64371-60343></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-177/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>11 Mar 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Irina Vetter</strong>, Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter M. Grace</strong>, Department of Symptom Research, University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-177/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-177/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding chemotherapy-induced...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-177/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-177/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-177/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gordon-Williams R and Farquhar-Smith P');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-177/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-177",
            templates : {
                twitter : "Recent advances in understanding chemotherapy-induced peripheral.... Gordon-Williams R and Farquhar-Smith P, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-177/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding chemotherapy-induced peripheral neuropathy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding chemotherapy-induced peripheral neuropathy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21625/23837")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23837");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "60342": 0,
                           "60343": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "cf0adb5f-0c60-444d-a96c-1bfb8483377d";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-177.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-177.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-177.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-177.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-177.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>